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ABSTRACT      
 
Esophageal cancer is the eighth most common cancer in the world, consisting of two major histological 
types: squamous cell carcinoma (dominant globally) and adenocarcinoma (rapidly increasing in incidence 
in the Western world during the last decades). Established risk factors for adenocarcinoma are 
gastroesophageal reflux symptoms, obesity and tobacco smoking, whereas squamous cell carcinoma is 
mainly associated with tobacco smoking and excessive alcohol intake. Esophageal cancer predominantly 
affects men; the gender difference in squamous cell carcinoma cases is entirely explained by the higher 
prevalence of risk factors in men, but the striking 7:1 sex ratio in adenocarcinoma remains unexplained. 
Esophageal cancer carries a very poor prognosis and despite efforts to improve survival the overall 5-year 
survival rate is still less than 10%, emphasizing the need for preventive factors. This thesis focuses on the 
etiology of esophageal cancer and the unexplained male predominance in esophageal adenocarcinoma.  
 
The first paper investigates differences in risk factor profiles between women and men as a possible 
explanation for the male predominance in esophageal and cardiac adenocarcinoma. The paper was based 
on a nationwide population-based case-control study of all newly diagnosed cases of adenocarcinoma 
(n=451) and corresponding controls (n=816) in Sweden between 1994-1997. Contradictory to the 
hypothesis, the point odds ratios (OR) did not indicate any weaker association of the established risk 
factors reflux, obesity and tobacco smoking with risk of esophageal adenocarcinoma in women (4.6, 10.3, 
and 5.3, respectively) compared to men (3.4, 5.4, and 2.8, respectively). Protective factors such as a high 
intake of fruit and vegetables or infection with Helicobacter pylori showed no stronger protective effect in 
women. Thus, gender differences in the exposure to known risk factors do not seem to explain the male 
predominance in esophageal or cardia adenocarcinoma.  
 
The second paper investigated if the higher incidence rate of esophageal adenocarcinoma in the United 
Kingdom compared to Sweden is explained by a higher population prevalence of established risk factors. 
Investigations were based on identical questionnaires filled out by a random sample of the English 
(n=3633) and Swedish (n=1483) populations. The prevalence of gastroesophageal reflux symptoms and 
obesity were significantly higher in the English population (OR 2.0, 95% CI 1.6-2.4 and OR 1.8, 95% CI 
1.5-2.1), suggesting that the higher incidence of esophageal adenocarcinoma in the United Kingdom is at 
least partly due to the higher population prevalence of well-established risk factors.  
 
The third paper investigates why surgical intervention of reflux does not provide protection against 
esophageal adenocarcinoma. All esophageal or cardia adenocarcinoma cases among antireflux operated 
patients in Sweden in 1965-2006 were identified and compared with matched controls from the same 
antireflux cohort. Recurrence of reflux after surgery was a risk factor for esophageal adenocarcinoma 
(OR 3.1, 95% CI 1.5-6.3), while BMI, tobacco smoking and type of antireflux surgery appeared to be of 
lesser importance. Recurrent reflux can explain the lack of a cancer protective effect of antireflux surgery 
and endoscopic surveillance might be an option for these patients.  
 
The fourth paper investigates the association between infection with human papillomavirus (HPV) and 
tumor location in the esophagus. The hypothesis is based on an oral route of transmission and an 
association between HPV and oropharyngeal squamous cell carcinoma. Available tumor material from 
esophageal squamous cell carcinomas in the Stockholm County in 1999-2006 was collected and 
examined for presence of HPV using multiplex polymerase chain reaction (PCR) with Luminex. No 
increased occurrence of HPV DNA was observed in esophageal squamous cell carcinomas located in the 
proximal compared to a more distal part of the esophagus. The prevalence of HPV DNA (10%) was low, 
and the identified HPV did not seem to be biologically active, based on p16INK4a data.  
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INTRODUCTION      
 
 
Esophageal cancer is the eighth most common cancer and the sixth most common cause of 
cancer mortality in the world.1 There are two major histological types of esophageal cancer, 
squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma dominates globally,2 
however, the incidence of adenocarcinoma has increased rapidly during the last decades and 
now accounts for more than 50% of esophageal cancers in the Western world.3 4 Established 
risk factors for esophageal adenocarcinoma are gastroesophageal reflux symptoms,5 obesity6 7 
and tobacco smoking,7 while squamous cell carcinoma is mainly associated with tobacco 
smoking and excessive alcohol intake.8 9 Esophageal cancer predominantly affects men. The 3:1 
male to female ratio in squamous cell carcinoma is explained by the difference in prevalence of 
risk factors between the genders,10 although the striking 7:1 ratio in adenocarcinoma remains 
unexplained.11  
Due to the elastic properties of the esophagus and the general aggressiveness of this type of 
cancer, tumors have usually proceeded to an advanced stage prior to diagnosis. More than 50% 
of patients have an unresectable tumor or distant metastasis at the time of diagnosis12 and even 
though efforts have been made to improve treatment, the overall 5-year survival rate is still 
below 10%,13 stressing the need for preventive factors.  
 
This thesis, based on four original papers, focuses on etiological factors for esophageal cancer, 
including the male predominance in esophageal adenocarcinoma and aims at increasing the 
knowledge and reducing the incidence of esophageal cancer in the future.  
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BACKGROUND      
 
The esophagus 
 
 
Anatomy 
 
The esophagus, a long flattened muscular tube and the first section of the gastrointestinal tract, 
begins at the pharyngoesophageal junction, approximately 18 cm from the incisors and is 
anatomically divided into three parts (Figure 1): the proximal- (≤ 23 cm from the incisors), the 
middle- (24-32 cm), and the distal esophagus (32-40 cm).14 The esophagus can distend up to a 
couple of cm when food passes, although the cervical and thoracic sections of the esophagus 
are collapsed when in the resting state.15  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Location and anatomical parts of the esophagus. Reprinted in agreement with the fair use 
policy.  
 
 
The esophagus is located within the thoracic cavity and passes anteriorly to the vertebrae, close 
to the trachea, pericardium and aorta, before it continues through the diaphragm and ends in the 
esophagogastric junction within the abdomen. The upper (UES) and lower esophageal 
sphincters (LES) create two high-pressure regions, limiting the esophagus and preventing 
gastroesophageal reflux. The LES consists of two muscle layers, an extrinsic (diaphragmatic 
component) and an intrinsic layer (esophageal muscle fibers). LES pressure increases or 
decreases in accordance with respiration and food intake.15   
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Histology  
 
The esophageal wall consists of a thick mucosa, with non-keratinized squamous cell 
epithelium, submucosa, with submucosal glands and Meissner’s nerve plexus, and muscularis 
propria, an outer and inner muscle layer contributing to esophageal motor functions and 
consisting of striated muscles in the cervical part and smooth muscles in the abdominal part of 
the esophagus. Within the thoracic part of the esophagus is the transition zone where no 
significant contraction occurs.15 The esophagus lacks an outer layer, i.e. the serosa, and ends 
with the adventitia.  
 
Clinical aspects 
 
Esophageal anatomy and histology contribute to the high mortality rates in esophageal cancer. 
Important aspects are the esophageal ability to distend when food passes through, which 
enables tumors to be large before symptoms occur. In addition, the anatomic location of the 
esophagus results in rapid tumor spreading and difficulty in tumor extirpation. Consequently, 
more than 50% of patients have unresectable tumors or visible metastasis at the time of 
diagnosis.12 Another aspect includes the thick mucosal layer and lack of a serosa layer which is 
clinical relevance in the event of surgical reconstruction, since the technique for anastomoses 
involves the strong mucosal layer, which is not necessarily present in other gastrointestinal 
organs.  
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Esophageal cancer 
 
 
Histological types 
 
There are two main histological types of esophageal cancer which together account for more 
than 90% of all esophageal cancers worldwide:16 adenocarcinoma (a malignant neoplasm of 
epithelial origin which grows in a glandular pattern),17 and squamous cell carcinoma (a 
malignant neoplasms of squamous cell epithelial origin).17 Squamous cell carcinoma is 
dominant worldwide, responsible for more than 90% of all esophageal cancers in developing 
countries.2 However, during recent decades the incidence of adenocarcinoma has risen rapidly 
in many industrialized populations, making adenocarcinoma responsible for approximately 
50% of all esophageal tumors in the Western world.4  
 
 
Pathogenesis 
 
The pathogenesis of esophageal cancer is not fully understood, but it has been suggested that a 
series of genetic changes associated with chronic inflammation gives cells carcinogenic 
properties (resistance to growth inhibitory signals and apoptosis, autonomous cell proliferation, 
unlimited replication, angiogenesis, invasion, and metastasis), resulting in survival benefits for 
mutated cells which outcompetes normal cells.18 Chronic inflammation is thought to be the 
causal factor of both adenocarcinoma and squamous cell carcinoma of the esophagus, although 
risk factors (described below) differ.19  
 
More than 80% of esophageal adenocarcinomas20 develop from Barrett’s esophagus (BE),21 
defined as an endoscopic visible columnar lined epithelium in the tubular esophagus with 
biopsy-confirmed intestinal metaplasia.22 However, tumors may also develop from submucosal 
glands or occasionally within the ectopic gastric epithelium located within the esophagus.23 
Squamous cell carcinoma develops from the normal non-keratinized squamous cell mucosa.  
 
 
Tumor location and the esophagogastric junction 
 
Tumor locations differ according to histological type: where adenocarcinoma is concerned, 
three quarters of the tumors are located in the distal esophagus, and in the case of squamous cell 
carcinoma, the tumors are more equally distributed between the middle and distal sections.12 16 
The less common cervical tumors are typically squamous cell carcinomas.12 16  
 
 
Esophagogastric junction  
 
The esophagogastric junction is an anatomic region located where the esophagus ends and the 
stomach starts identified clinically by means of endoscopy as “the upper margin of the 
longitudinal folds of the stomach”.24 Tumors of the esophagogastric junction are classified 
according to the often cited Siewert’s definition from 1998 namely as tumors “that have their 
center within 5 cm proximal and distal of the esophagogastric junction” (Figure 2).  
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Figure 2: The Siewert’s definition of the esophagogastric junction. Reprinted with permission from 
Springer Link.  
 
 
 
Furthermore, tumors in the esophagogastric region are divided into type I if localized 1-5 cm 
proximal of the esophagogastric junction, type II if localized 1 cm proximal to 2 cm distal of 
the esophagogastric junction, and type III (also known as cardiac) if localized 2-5 centimeters 
distal of the esophagogastric junction.20 There is a long and still ongoing controversy as to 
weather adenocarcinomas of the esophagogastric junction should be classified and treated as 
esophageal or gastric adenocarcinomas.20 25 Tumors of the esophagogastric junction share many 
similarities with esophageal adenocarcinomas: both develop from the columnar cell epithelium 
of the gastroesophageal junction,26 and both have a similar risk factor profile (gastroesophageal 
reflux symptoms5 27 and obesity28 29 increase the risk, whereas infection with Helicobacter pylori 
generates a protective effect (inverse compared to gastric cancer),30 although the risk factors for 
esophagogastric adenocarcinoma are typically weaker than for esophageal adenocarcinoma). 
Age and sex are also equally distributed, with most tumors occurring in males over 65 years.26 
31 In this thesis, as a result of these similarities, esophagogastric adenocarcinomas were 
included in the investigations on etiology of esophageal adenocarcinoma in papers I and III. In 
paper I, the esophagogastric junction is defined as 2 centimeters proximal and 3 centimeters 
distal of the esophagogastric junction (this classification was used prior to Siewert’s definition), 
whereas in paper III, the Siewert’s definition is used.   
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Risk factors  
 
Adenocarcinoma 
 
Barrett’s esophagus 
 
BE is considered to be the premalignant condition for esophageal adenocarcinoma32 and the 
opinion that the majority of esophageal adenocarcinoma cases arise from BE is well 
established.21 BE develops from repeated mucosal injury and inflammation as a result of long-
standing gastroesophageal reflux disease (GERD).33 34 The true population prevalence of BE is 
difficult to establish due to the asymptomatic properties of the condition but population-based 
studies indicate a prevalence of 1.6-6.8%.35 BE increases the risk of esophageal 
adenocarcinoma 30 to 60 times when compared to the general population.36-38 However, only a 
minority of patients with BE develop esophageal adenocarcinoma with an incidence rate of 
between 1.2-6.3 cases per 1000 person-years and an annual risk of 0.1-0.6%.37 38 39 40 Although 
BE increases the relative risk of esophageal adenocarcinoma greatly, the absolute risk of 
developing the disease is limited and the overall mortality in BE patients is similar to that of the 
general population.41  
 
Gastroesophageal reflux symptoms, obesity and tobacco smoking 
 
Gastroesophageal reflux symptoms and obesity are the two major risk factors for esophageal 
adenocarcinoma (further addressed below). Symptoms of gastroesophageal reflux increase the 
risk of esophageal adenocarcinoma 2 to 8 times 5 7 42 and the risk is further increased among 
patients with more severe (higher frequency/duration/severity) reflux symptoms.5 Obesity, 
particularly of the abdominal type, increases the risk of esophageal adenocarcinoma between 2 
and 4 times, seemingly independently of gastroesophageal reflux symptoms.6 Tobacco smoking 
(addressed further below) is a moderate risk factor for esophageal adenocarcinoma and 
increases the risk by approximately 50%.7 43 When gastroesophageal reflux symptoms and a 
high BMI are combined, the risk is increased more than expected suggesting an amplifying 
association, whereas no such effect has been observed when gastroesophageal reflux symptoms 
or obesity are combined with tobacco smoking.7  
 
Other risk factors  
 
High socioeconomic status, male gender,44 Caucasian race 45 and achalasia46 have also been 
reported to increase the risk of esophageal adenocarcinoma whereas infection with H. pylori,47 
low socioeconomic status44 and dietary factors, such as the intake of antioxidants48 and high 
intake of fruit and vegetables,49 have shown to have a protective role against esophageal 
adenocarcinoma. Alcohol drinking is not considered as a risk or protective factor for esophageal 
adenocarcinoma, however, it has been indicated that a moderate intake of wine might decrease 
the risk.50 51 Several studies support the hypothesis of aspirin and non-steroidal anti-
inflammatory drugs (NSAIDs) reducing the risk of esophageal adenocarcinoma52 53 although 
the results are partly conflicting. Supporting studies have shown that treatment with selective 
cyclooxygenase-2 (COX-2) inhibitors reduces tumor growth in vitro54 and a large Australian 
study showed a 9 times reduced risk of esophageal adenocarcinoma in patients using 
aspirin/NSAIDs at least weekly,55 however, other studies have shown no such preventive 
effect.53 56 More research, including results from ongoing randomized clinical trials, are needed 
in order to clarify the role of aspirin/NSAIDs in esophageal adenocarcinoma.  
  8 
Hereditary risk factors 
 
Although familial clusters of both BE and esophageal adenocarcinoma have been reported,57 
family history of digestive cancers has not been found in population-based studies.58 59 
Dominating risk factors for esophageal adenocarcinoma are non-genetic, implying that genetic 
factors are of limited importance in the development of this type of cancer.  
 
 
Squamous cell carcinoma  
 
Tobacco and alcohol  
 
Tobacco smoking and high alcohol intake are the two major risk factors for esophageal 
squamous cell carcinomas and responsible for more than 90% of all cases in industrialized 
countries.8 The risk of cancer rises with increased quantity and duration of smoking,8 and an 
intake of at least 50 grams of alcohol per day raises the risk of squamous cell carcinoma two to 
three times.9 Furthermore, the risk of cancer further increases when smoking and alcohol are 
combined.8 9 Genetic studies also indicate that populations with a deficiency in alcohol 
dehydrogenase, an enzyme catabolizing ethanol, have a greater risk of squamous cell carcinoma 
due to alcohol consumption, compared to populations with a normal active enzyme.60 
Smokeless tobacco, such as chewing of betel quid (a mixture of areca nut, tobacco and slaked 
lime, wrapped in a betel leaf) and snuff use, has also been suggested to increase the risk of 
esophageal squamous cell carcinoma although results are not conclusive.61-63  
 
 
Other risk factors 
 
Low socioeconomic status12 and humans with a dark skinned phenotype 8 64 are other well-
established risk factors for esophageal squamous cell carcinoma. Esophageal diseases, such as 
longstanding achalasia, may well contribute to increased risk.65 66 Occupational exposure to 
metal dust such as chromium (hexavalent chromium),67 cadmium and lead68 also seems to 
increase the risk as does having a stressful occupation with high demand and low control (when 
measured with a demand-control model69). The role of infectious agents has also been 
investigated: Human papillomavirus (HPV) is thought to be a risk factor (further addressed 
below) although. H. pylori 70 71 and Epstein-Barr virus (EBV) have been ruled out as having any 
causative effect in esophageal squamous cell carcinoma.72 Dietary factors contributing to 
esophageal squamous cell carcinoma include pickled food,73 hot beverages especially tea74 and 
manté,75 and ingestion of lye or caustic fluids,76 whereas a protective effect has been suggested 
from high intake of fruit and vegetables49 77 and animal studies indicate that green tea might be 
protective, although epidemiological human studies are inconclusive.78  
 
 
Hereditary risk factors 
 
The etiological role of heredity in squamous cell carcinoma is not likely to be of major 
importance,58 although a few families inherit the autosomal dominant skin disorder tylosis (non-
epidermolytic palmoplantar keratoderma), a gene abnormality on chromosome 17q25 
responsible for the development of esophageal cancer in 90% of patients by the age of 70,79 80  
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Incidence and mortality 
 
Worldwide 
 
Esophageal cancer is the eighth most common cancer and the sixth most common cause of 
cancer mortality in the world.1 According to the GLOBACAN produced by the World Health 
Organization (WHO), more than 482,000 people were diagnosed with and 407,000 died from 
esophageal cancer in 2008 with the highest incidence and mortality rates found in developing 
countries (83 and 86% respectively).1 The highest incidence of esophageal cancer worldwide is 
found in Zhengzhou, the capital of the Henan province in China, where 100 cases per 100,000 
people are found in men and more than 50 in women.1 High-risk regions, with incidence from 
30 per 100,000 people and above, are also found in Iran, Central China, South Africa, Southern 
Brazil, Northern Italy and France (Normandy and Calvados).81 Northern Europe and Northern 
America have, in general, a more moderate incidence rate (5.7 versus 8.3 cancer cases per 
100,000 people) compared to Africa (26.8-34.5 cancer cases per 100,000 people) and South-
Central Asia, including China (24.6 cancer cases per 100,000 people).82  
 
The incidence of adenocarcinoma and squamous cell carcinoma varies greatly around the 
world. Since the rapid increase in incidence of adenocarcinoma during the last decades,4 it now 
accounts for more than 50% of esophageal cancer cases in the Western world with the highest 
incidence found in the United Kingdom (7.0 cancer cases per 100,000 people).45 Squamous cell 
carcinoma is, however, the dominating type in high-risk areas and accounts for more than 90% 
of esophageal cancer cases in developing countries.2 Much of the variance in incidence between 
the two histological types is suggested to be due to ethnic differences, since the same incidence 
pattern of esophageal cancer is observed in an American study comparing humans with black 
(87% squamous cell carcinomas) with humans with white (55% adenocarcinomas) skinned 
phenotype in the United States.3  
 
 
Incidence trends worldwide 
 
The total worldwide incidence of esophageal cancer has been stable during the last few 
decades, however, the incidence of different histological types has changed greatly in the 
Western world. The incidence of esophageal adenocarcinoma has increased as much as a seven-
fold (from 3.6 to 25.6 cancer cases per 100,000 people) during the last three decades in both 
North America4 and Europe,3 11 83 including Sweden.84 85 The greatest increase was observed 
until the middle 1990s and, even though the increase has slowed, it still seems to be consistent.4 
At the same time, the incidence of squamous cell carcinoma has decreased making the overall 
incidence of esophageal cancer stable in Western populations.44  
 
Due to misclassification of tumor location, little is known about the incidence of 
esophagogastric adenocarcinomas worldwide, however, the incidence seems to follow the 
rising trend of esophageal adenocarcinomas, albeit to a more moderate extent.31 86 87  
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Incidence in Sweden 
 
There are approximately 440 (443 in 2009) new cases of esophageal cancer in Sweden every 
year.88 Incidence rates are low compared to high-risk nations, 2.9 per 100,000 in men and 0.9 
per 100,000 in women.88 The incidence trend of esophageal cancer is similar to that in other 
Western countries with a rapid increase in the incidence of esophageal adenocarcinoma during 
the last decades.84 85 89 The incidence is also continuing to rise although at a much slower pace, 
and a similar pattern is observed in gastric cardia adenocarcinoma.89 The incidence of 
esophageal squamous cell carcinoma was fairly stable until the beginning of the 1990s where it 
has thereafter decreased,84 85 89 resulting in an overall stable incidence of esophageal cancer in 
Sweden during the last decades.85  
 
 
Sex ratio 
 
Esophageal cancer predominantly affects men, with a male to female ratio of 1.1-3:1 for 
squamous cell carcinoma11 84 90 and 3-10:1 for adenocarcinoma.11 20 44 84 90 In Europe, the United 
Kingdom (UK) has a male to female ratio of 5-5.5:1 for esophageal adenocarcinoma11 44 
compared to 4:1 in Sweden.84 Differences in gender ratio for squamous cell carcinoma are 
completely explained by the difference in prevalence of risk factor exposure from tobacco 
smoking and alcohol.10 The male predominance in esophageal adenocarcinoma is, however, 
unexplained. Higher production and concentration of gastric acid,91 higher prevalence of hiatus 
hernia, abnormal 24-hour pH test and defective LES in patients with symptomatic 
gastroesophageal reflux,92 abdominal/android obesity93 resulting in higher intra-abdominal and 
intra-gastric pressure are all more common in men and have been suggested to explain male 
predominance, although no conclusive results have been presented.94 Estrogen exposure may 
not be a causative factor.95 96  
 
 
Symptoms 
 
Dysphagia and weight loss are the two most frequent symptoms in patients with esophageal 
cancer and are reported by 74% and 57% of the patients respectively.16 Dysphagia usually 
occurs when the lumen diameter is less than 13 mm,97 and weight loss is secondary to cancer 
cachexia, dysphagia per se and change in diet due to dysphagia.97 Less frequently reported 
symptoms are odynophagia (pain when swallowing food) reflecting advanced local invasion 
and is reported in 17% of patients,16 dyspnea due to pleural effusion, hoarseness and coughing 
reflecting tumor overgrowth of the laryngeal nerve, and lymphadenopathy reflecting metastatic 
disease.12  
Due to the elastic nature of the esophagus, symptoms usually occur at a later stage and more 
than 50% of patients have unresectable tumors or visible metastasis at the time of diagnosis.12 
Currently, there are no effective methods for detecting esophageal cancer at an early stage.19 
Surveillance of patients with BE has been suggested, yet since the incidence of cancer is also 
low in these patients (0.1-0.6%),37 38 39 40 it is difficult to identify feasible and cost effective 
measures of surveillance. Screening has also been suggested for patients with a profile of severe 
GERD and obesity, although the high prevalence of individuals with these known risk factors 
combined with the low incidence of esophageal cancer makes it unrealistic to implement.98 
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Diagnosis 
 
An esophageal cancer diagnosis is usually confirmed by endoscopic visualizing of tumor mass 
and histological verification with biopsies. Additional investigation techniques at specialized 
centers include endoscopic ultrasound which accurately determines both local and regional 
tumor borders,99 and a combination of computer tomography (CT) with positron emission 
tomography (PET) which is the best way to determine tumor spreading.100 Tumors are staged 
according to the tumor-node-metastasis (TNM) classification which is based on tumor depth of 
wall invasion, (T0-T4), occurrence of regional lymph nodes (N0-N1) and occurrence of distant 
metastasis (M0-M1).101  
Patient fitness is measured taking into account comorbidities, biological age, physical activity 
and, in some cases, spirometry and treadmill results.2  
 
 
Treatment  
 
Treatment can either be curative or palliative and is individually tailored, ideally based on a 
multidisciplinary team decision that is arrived at using the summary of diagnostic findings and 
patient fitness.2 
 
 
Curative treatment  
 
Curative treatment is based on surgical resection with or without neoadjuvant chemotherapy or 
chemoradiotherapy.2 The preoperative treatment has been investigated in several studies, 
although underpowered and no treatment has been clearly superior to the others.2 Currently the 
typical treatment used for the most common tumor stages considered for surgery (stage II-III) is 
chemotherapy followed by esophagectomy.102  
Although surgery is the curative treatment of choice, data from case series have also indicated 
that curative results can be achieved with chemoradiotherapy alone, especially in older patients 
that are deemed not suitable for surgery.103 The effects of such treatment and preoperative 
oncologic treatment can be evaluated using the combined PET and CT technique.104  
 
 
Palliative treatment  
 
Most patients (75%) with esophageal cancer have an advanced tumor stage or poor physical 
condition making them unsuitable for curative treatment.102 The palliative treatment focuses on 
relieving dysphagia (preferably through self-expanding metallic stents or intraluminal 
brachytherapy105) pain therapy and feeding. Consistent for all palliative care, is that it should be 
performed by experienced staff in order to meet patient needs in the best possible way.2 
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Prognosis 
 
Patients are often diagnosed at an advanced stage resulting in an overall 5-year survival rate of 
less than 10% in Europe.13 Young patients with less advanced tumor stage have a better chance 
of surviving (20% below 50 years,85 and 95% of patients with carcinoma in situ with no 
metastasis or lymphatic nodes involved survive for at least 5 years).12 However, in reality most 
patients are older and diagnosed with an advanced tumor resulting in very poor chance of 
survival. Patients treated with palliative care have only a median survival of less than a year.12 
Weight loss more than 10% is an independent indicator for poor prognosis.12 New data, not yet 
published from our group, indicates that the overall 5-year relative (disease-specific) survival in 
Sweden between 2000 and 2009 has improved to 15% in both esophageal and gastric cardia 
adenocarcinoma whereas the 5-year survival of squamous cell carcinoma remains at 10%. 
Tumor recurrence most often occurs within 1-year postoperatively giving 3-year survivors 
virtually the same prognosis as the overall population.106   
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Risk factors addressed in this thesis 
 
 
Adenocarcinoma 
 
 
Gastroesophageal reflux disease 
 
 
Definition 
 
GERD is defined according to the Montreal Definition and Classification of GERD as “a 
condition that develops when reflux of the stomach contents causes troublesome symptoms 
and/or complications”.107 Symptoms are defined as “heartburn or regurgitation” and 
troublesome is defined as “when symptoms adversely affect an individual’s well being”. In 
population-based studies the definition “mild symptoms occurring 2 or more days a week” 
should be used and in clinical settings the definition “patient should determine if their reflux 
symptoms are troublesome” should be used.107  Esophageal complications are defined as 
“reflux esophagitis, hemorrhage, stricture, Barrett’s esophagus and adenocarcinoma” and the 
Montreal definition also states that “long segment Barrett’s esophagus with intestinal 
metaplasia is the most important identified risk factor for esophageal adenocarcinoma”.107  
The concept of GERD is very wide and it took a long time before researchers around the world 
agreed on a joint definition. The Montreal definition of GERD was not completed and agreed 
upon until 2006 making it hard to compare and compile results from prior studies, because of 
the different definitions used. Further complicating matters, population-based studies show that 
not all patients with symptomatic gastroesophageal reflux have complications108 such as 
esophagitis and that not all patients with complications have gastroesophageal reflux 
symptoms,108 making it even harder to study GERD because ethical considerations limit the use 
of large population-based endoscopic studies.  
In this thesis, the term gastroesophageal reflux symptoms will be used instead of GERD in 
papers I-III, in response to the Montreal definitions and the design of questionnaires.  
 
 
Pathogenesis 
 
General 
 
In a healthy individual, a physiological antireflux barrier prevents the reflux of gastric acid into 
the esophagus by three main mechanisms: i) the static antireflux barrier, created by the 
intrinsic part of the LES keeping a normal resting pressure (15-35 mmHg),109 ii) the dynamic 
antireflux barrier, created by the extrinsic part of the LES/the crural diaphragm where pressure 
varies with breathing and iii) the His angle or the flap valve mechanism formed by the sharp 
angle between the distal esophagus and the gastric cardia within the stomach.109 If the pressure 
of the inner LES is lost, reflux can still be prevented through maintained crural diaphragmatic 
contractions.109  
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Reflux episodes can occur through three different mechanisms:110 
 
¥ Transient LES relaxation - simultaneous relaxation of both the static and dynamic 
antireflux barrier unrelated to food intake.109  
¥ Transient increase of abdominal pressure.  
¥ Spontaneous free reflux, associated with a constantly low LES pressure. No apparent 
decrease of LES pressure or increase of abdominal pressure occurs, although gastric 
reflux is developed.  
 
Patients with esophagitis are reported to experience all three mechanisms whereas transient 
LES relaxation only occurs in healthy controls.110  
 
 
Hiatus hernia 
 
Patients with hiatus hernia, a condition in which parts of the stomach are proximally displaced 
above the diaphragm, are reported to have more severe gastroesophageal reflux symptoms 
compared to other patients.111 112 Suggested mechanisms for increased severity include:109 112 113 
 
¥ Impaired or prolonged acid removal from the esophagus.   
¥ Acid, trapped in the hernia sac, is forced backwards into the esophagus when the 
crural diaphragm contracts.  
¥ The diaphragm might be largely widened which will prevent the crural diaphragm 
from functioning properly.  
¥ Absence of His angle, defined above.  
 
 
Other factors 
 
Obesity, especially abdominal, is known to increase gastroesophageal reflux symptoms by 
means of increased abdominal pressure.114 Delayed gastric emptying, increased gastric acid 
secretion, delayed esophageal acid clearance and decreased tissue resistance are also important 
factors contributing to gastroesophageal reflux.111 The intake of anticholinergic medications has 
also been suggested to increase GERD through the relaxation of LES but results are conflicting 
and inconclusive.115 116  
 
 
Incidence and prevalence 
 
The prevalence of GERD differs in different parts of the world with the highest figures in the 
Western world where 10-20% of the population is affected.117 118 Population-based studies from 
the United States have also reported a prevalence of 10-20%, with a higher prevalence in 
humans with black skinned phenotype compared to those with white skinned phenotype.117 
Similar results from Europe show a prevalence of 10-18% in the UK (although as much as 41% 
of the population reports that they have had gastroesophageal reflux symptoms within the last 
six months),119 120 17% in Sweden, 15% in Finland and 10% in Spain.117 GERD is also a 
growing problem in children and a recent report from the UK showed a high prevalence (8%) 
of gastroesophageal reflux symptoms, particularly in girls aged 16-17 years,121 although 
symptoms do not seem to increase with age.122 
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Treatment of GERD 
 
Medical 
 
Histamin-2-receptor antagonists (H2RA) and proton pump inhibitors (PPI) have, during the last 
few decades, been the two dominant medical treatments for gastroesophageal reflux symptoms. 
H2RAs block the H2-receptors and PPIs block the proton pumps (H+ K+ ATPase) in the parietal 
cells of the gastric mucosa, preventing acid release.123 PPI has advantages over H2RA including 
better symptom relief (in 80 versus 60% of patients)124 and mucosal healing (in 78 versus 50% 
of patients)125 and should be considered the “drug of choice” for gastroesophageal reflux 
symptoms. PPI also has relatively few short- and long-term side effects, although it should not 
be forgotten that PPI has been connected with an increased risk of osteoporosis,126 
pneumonia,127 infection with Clostridium difficile128 and interaction with Clopidogrel.129 
Medical treatment is effective in most patients although, for unknown reasons, some patients do 
not respond to medical treatment of GERD and other treatment methods, such as surgery, are 
required.  
 
 
Surgical  
 
Indications for surgical treatment are persistent clinical symptoms despite adequate medical 
treatment in patients with endoscopically confirmed mucosal damage due to gastroesophageal 
reflux or an unwillingness for lifelong medical treatment of GERD symptoms.130 131  
The surgical technique used is almost exclusively fundoplication; the most common procedures 
are Nissen (posterior 360°) or the Toupét (posterior partial). Both of these fundoplication 
techniques are initiated with the closure of the diaphragm crura and more or less extensive 
mobilization of the gastric fundus which is then later pulled behind the esophagus and attached. 
The two techniques differ in the attachment of the gastric fundus. The Nissen fundoplication 
attaches the gastric fundus to “itself” creating a 360° fundic wrap around the distal 
esophagus.132 133 The Toupét fundoplication attaches the gastric fundus to three different 
locations; the right diaphragm crus and both lateral parts of the esophagus thus creating a partial 
loop around the posterior esophagus.133 134  
Studies report that more than 90%131 of all patients are free from gastroesophageal reflux 
symptoms after surgery, however, side effects including dysphagia, gas, bloating, inability to 
belch or vomit and the recurrence of gastroesophageal reflux symptoms develop in some 
patients.130 131  
Several studies have tried to conclude which surgical antireflux technique is superior to the 
other but there is no proven notable difference reported in gastroesophageal reflux prevention. 
135 However, the incidence of side effects differs in favor of Toupét fundoplication.133 136 
Laparoscopy and laparotomy approaches137-139 have also been compared although the results are 
inconclusive, indicating that the surgical result might depend more on patient selection, surgical 
skills and hospital methods, than approach.140  
 
Two large trials conducted in Sweden have compared the outcome of patients treated with 
medication or antireflux surgery. Both show slightly better reflux control in the surgical group, 
although the incidence of side effects was also higher in this group.141 142  
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Gastroesophageal reflux and esophageal adenocarcinoma  
 
Symptomatic gastroesophageal reflux was established as the strongest risk factor for esophageal 
(and gastric cardia) adenocarcinoma in 1999.5 A Swedish population-based case-control study 
demonstrated an eight–fold increased risk of esophageal adenocarcinoma in patients with 
heartburn, regurgitation or both, occurring at least once a week. Furthermore, the risk increased 
with frequency, severity and duration of symptoms and, for longstanding and severe 
gastroesophageal reflux symptoms, the odds ratio for esophageal adenocarcinoma was 43.5.5 
Since 1999, several large and population-based studies7 27 143 have confirmed these findings, 
showing a dose-response association between gastroesophageal reflux symptoms and 
esophageal (and gastric cardia) adenocarcinoma, where the risk of cancer increases with 
symptom severity.144  
 
 
Antireflux treatment and esophageal adenocarcinoma 
 
The association between gastroesophageal reflux symptoms and esophageal adenocarcinoma 
implies that the risk of cancer should be reduced with the medical or surgical treatment of such 
symptoms.145 However, no such effect has been shown and current guidelines state that 
antireflux surgery should not be performed as a protective measure against cancer 
development.27 146-149 Recurrent reflux after surgery has been suggested as an explanation for the 
failed protective effect of antireflux surgery, although results were inconclusive.150 Some 
studies even indicate that failed antireflux surgery can further increase the risk of esophageal 
adenocarcinoma. 151 The medical treatment of gastroesophageal symptoms also lacks a 
protective effect for esophageal and cardia adenocarcinoma and studies have shown that 
patients with mild rather than severe symptoms treated with PPIs have a higher risk of 
developing both BE and esophageal adenocarcinoma.34 152  
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Overweight and obesity  
 
 
General  
 
During recent decades the Western world has experienced an “obesity epidemic” where the 
number of obese people has doubled since 1980.153 In 2008, 1.5 billion people were considered 
overweight, 500 million were obese and the number will continue to rise.153 The prevalence of 
obesity in Sweden is lower (10%) than in many other countries154 whereas the UK has a much 
higher prevalence (23%).155  
Obesity is associated with increased risk of several malignant tumors (thyroid, breast, colon, 
kidney, liver, gall bladder, pancreas and endometrium)156 157 and the association between 
obesity and esophageal adenocarcinoma seems to be one of the strongest, especially in men.157 
It has been suggested that the rapid increase in incidence of esophageal adenocarcinoma might 
be explained by the similarly rapid increase of obesity in the Western world.  
 
 
Measurement 
 
Several methods have been developed to measure overweight and obesity. Body mass index 
(BMI), a rather rough measurement often used in epidemiologic studies, is calculated by 
dividing the individual’s body weight in kilograms by their height in meters squared. BMI is 
defined according to the WHO as underweight (<18.5), normal weight (18.5-24.9), overweight 
(25.0-29.9) and obesity (≥30).153 Although BMI has many advantages, it lacks the ability to 
describe body composition and fat distribution. When interested in these dimensions, 
anthropometric measurements (waist circumference and waist hip ratio), radiologic techniques 
(CT scan measuring the intra-abdominal fat), biometrical impedance method (measuring fat 
free body mass)158 or dual-energy X-ray absorptiometry (providing an overall body 
composition)159 can be employed.  
 
 
Pathogenesis 
 
The molecular mechanism of the interaction between obesity and esophageal adenocarcinoma 
is not quite clear. Several studies have tried to investigate the relation between obesity and 
different types of cancer, including esophageal adenocarcinoma, providing a few conclusions, 
in brief:  
 
 
¥ The combination of polymorphisms in the gene of insulin-like growth factor 1 (IGF-
1) receptor together with obesity has been suggested to increase the risk of 
esophageal adenocarcinoma. A Canadian case-control study found that patients who 
were obese and carried the 1013G>A gene variant had a greater risk of cancer when 
compared with those who carried the 1013G>G gene.160  
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¥ Leptin, a hormone secreted from adipose tissue and increasing with rising BMI, has 
generally been suggested to activate epidermal growth receptors, stimulate cell 
proliferation and inhibit apoptosis.161 In addition, an upregulation of receptors for 
leptin and adiponectin (another adipocytokine) has been observed in patients with an 
advanced tumor stage thus suggesting the involvement of these factors in tumor 
biology.162 However, an Australian case-control study found no correlation between 
single nucleotide polymorphisms in the leptin receptor and esophageal 
adenocarcinoma,163 and another study found an inverse relation between tumor 
growth and adiponectin in animals,164 suggesting that the role of obesity in 
esophageal adenocarcinoma development needs further investigation.  
 
 
Obesity and esophageal adenocarcinoma  
 
The role of obesity as a risk factor for esophageal adenocarcinoma was introduced in three large 
population-based case-control studies in the 1990s 28 29 165 and was, during the last decade, 
confirmed in three large cohort studies.166-168 Individuals with a BMI above 30 have a two- to 
four-fold increased risk of developing esophageal adenocarcinoma compared with individuals 
with a BMI below 25166-168 and one study showed that a higher BMI, even within normal range 
(below 25), is correlated with an increased risk of cancer.168  
 
The association between obesity and esophageal adenocarcinoma could be readily explained by 
the mechanism that obesity increases the intra-abdominal pressure and, thereby, the frequency 
of gastroesophageal reflux. However, all studies assessing gastroesophageal reflux symptoms 
and obesity together show an independent association7 28 29 43 93 and individuals with both 
obesity and symptomatic gastroesophageal reflux have a considerably increased risk of cancer 
consistent with a synergetic interaction.7 Although it has been suggested that asymptomatic 
gastroesophageal reflux might be more common in obese individuals than in individuals with 
normal weight,169 170 obesity seems to be an independent risk factor for esophageal 
adenocarcinoma.6  
When further investigating obesity, it has been discovered that increasing abdominal diameter, 
after adjustment for BMI, is independently associated with an increased risk of esophageal 
adenocarcinoma.93 These results are striking and might contribute to the explanation of male 
predominance in esophageal adenocarcinoma,89 171 since the predominantly abdominal fat 
distribution is typically found in men.  
 
 
Tobacco smoking  
 
 
Tobacco smoking is one of the main risk factors for esophageal squamous cell carcinoma,8 
however, it is considered to be only a moderate risk factor for esophageal adenocarcinoma and 
relatively few studies have addressed this issue.32 Four large population-based studies have 
examined the relationship between esophageal adenocarcinoma and tobacco smoking with odds 
ratios varying from 1.4 to 2.27 43 172 and an increased risk was observed when combining 
tobacco smoking with other risk factors such as obesity.7 Interestingly, the increased risk of 
adenocarcinoma when exposed to tobacco smoking is similar for esophageal and cardia 
adenocarcinoma (1.5 versus 1.4 and 2.2 versus 2.6).43 172   
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Helicobacter pylori 
 
 
General 
 
Helicobacter pylori (H. pylori) is a spiral-shaped, gram-negative bacterium with a polar flagella 
which colonizes the surface of the human gastric mucosa by breaking down gastric acid to 
ammonia and carbon dioxide.173 This causes gastroduodenal inflammation which might then 
develop into atrophic gastritis leading to complications of vitamin B12 or iron deficiency 
anemia, gastric or duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) or non-
cardia gastric adenocarcinoma.174 175 Infection with H. pylori is the strongest known risk factor 
for peptic (60-80% of patients are infected) and duodenum ulcer (95% of patients are 
infected).176 Although H. pylori infection seems harmful, studies suggest that the bacterium has 
coexisted with humans since the beginning of humanity177 indicating that there must be some 
advantages associated with H. pylori.   
The prevalence of H. pylori infected individuals is decreasing rapidly178 with the presence of 
the bacterium in only 60% of the world population.179 The prevalence of carriers varies 
throughout the world and Western societies tend to have a lower prevalence than developing 
countries.179 The main route of transmission is not established although infections occur mostly 
before the age of 10 years.180  
Detection of H. pylori is performed through direct or indirect methods. Direct methods include 
endoscopy with collection of biopsy material and the disease is confirmed by means of 
histological examination, either directly or after growing the bacteria in culture. Indirect 
methods or noninvasive methods include the urea breath test and serology. The serologic test is 
especially useful in epidemiologic studies because of its low cost and the tests ability to detect 
past and present colonization.71  
 
 
Pathogenesis 
 
H. pylori contains two major virulent factors: vacuolating cytotoxin gene A (VacA) and 
cytotoxin associated gene A (CagA). VacA is a cytotoxin with several effects, including an 
ability to form a vacuolization in epithelial cells by forming a pore in late endosomal vesicles of 
the cell membrane. The pore has chloride channel activity and alternates the composition of 
anions within the endosome thus creating an osmotic swelling.173 VacA can also cause host 
cells to activate apoptosis after pore formation in mitochondrial membranes.181 VacA has a 
signal sequence (s) which can vary and strains of H. pylori with VacA of the s1 type are more 
highly associated with both ulcers and gastric cancer.182 The CagA protein was initially 
discovered as a marker for H. pylori infection, as it was discovered that individuals expressing 
antibodies against CagA tend to have a higher incidence of peptic ulcer and gastric 
adenocarcinoma.183 184 Cellular enzymes known to activate CagA are involved in carcinogenesis 
and CagA can stimulate the activation of growth factor receptors which then affects the 
structure and differentiation of epithelial cells.185  
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Helicobacter pylori and esophageal adenocarcinoma 
 
During the last decade, a number of studies have investigated the relation between H. pylori and 
the risk of esophageal adenocarcinoma. Results are mainly consistent and show that individuals 
colonized with H. pylori, particularly those positive for the virulent CagA strain,71 have a 
decreased risk of esophageal adenocarcinoma (OR 0.41, 95% CI 0.28-0.62).47 The suggested 
mechanism is that H. pylori reduces the production of gastric acid resulting in reduced 
gastroesophageal reflux30 186 and is further supported by the evidence that incidence of 
esophageal adenocarcinoma is low in parts of the world where the prevalence of H. pylori is 
high and vice versa.  
 
 
 
Fruit and vegetables 
 
 
Mechanism 
 
The theoretical mechanism for high intake of fruit and vegetables as a protective factor for 
esophageal adenocarcinoma is based on the belief that free radicals, known to promote 
carcinogenesis, are produced when chronic gastroesophageal reflux causes epithelial damage.187 
188 Fruit and vegetables are the major dietary source of antioxidants189 and are thought to bind 
and incapacitate the reactive oxygen spices resulting in a decreased risk of carcinogenesis.188  
 
 
Intake of fruit and vegetables and esophageal adenocarcinoma  
 
Several studies have indicated that a high intake of fruit and vegetables has an inverse effect on 
the development of both esophageal and cardia adenocarcinoma49 190-192 although it is difficult 
to study dietary factors due to the wide range of fruit and vegetables, recall bias and no 
universal measurements. Historically, retrospective case-control studies have shown a greater 
protective effect than cohort studies thus suggesting that recall and selection bias are 
important.190  
Recently published population-based studies showed a protective effect of high compared to 
low intake of fruit and vegetables for esophageal (OR 0.43, 95% CI 0.26-0.71) and cardia (OR 
0.63, 95% CI .39-1.01) adenocarcinomas, although the latter was not statistically significant.192 
Furthermore, when dividing exposure into subgroups, the intake of raw vegetables reduced the 
risk of esophageal adenocarcinoma (OR 0.81, 95% CI 0.68-0.98) whereas brassica vegetables 
reduced the risk of cardia adenocarcinoma (OR 0.72, 95% CI 0.54-0-95)191 and citrus fruits 
were found to be protective for both esophageal and cardia adenocarcinoma (OR 0.55 versus 
0.38) with an increased effect particularly pronounced among smokers.191  
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Squamous cell carcinoma 
 
 
Human papillomavirus 
 
 
History 
 
Human papillomavirus (HPV) is an enveloped closed-circular double-stranded DNA virus193 
and the main cause of cervical cancer.194 195 The carcinogenetic effect of the virus was first 
proposed in 1842 when observations showed that prostitutes had a high incidence of cervical 
cancer and that nuns had a complete absence of this type of cancer. 196 However, it was not until 
1983, more than a century of animal and human studies later, that HPV types 16 and 18 were 
isolated from cervical cancer tumors and classified as human carcinogens by the International 
Agency for Research on Cancer in 1995.197  
 
 
General  
 
HPV is part of the papovaviridae family which consists, as a group of papillomaviruses and 
polyomaviruses.198 Papillomaviruses infect a wide range of vertebrates but are highly species 
specific; they are named after the species they infect (e.g. human papillomavirus) and numbered 
in order of discovery. Papillomaviruses have a specific cellular tropism for squamous epithelia, 
and are associated with various benign lesions (warts and papillomas) as well as several 
invasive cancers (cervical, vulva, vagina, and oropharynx). More than 100 HPV types have 
been identified and categorized according to carcinogenic abilities in cervical cancer as: high-
risk (HR), putative high-risk (pHR), and low-risk (LR) types (Table 1).199  
 
 
 
 
Table 1. Classification of HPV types according to carcinogenic abilities.199  
 
 
High risk  16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
Putative HR  26, 53, 66 
Low risk  6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 
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Viral particle  
 
The viral genome consists of approximately 8,000 base pairs organized into three regions: the 
non-coding long control region (LCR), controlling viral transcription and the two open frame 
regions (ORF) consisting of the early (E) region, coding for regulatory proteins, and the late (L) 
region, coding for structural proteins. Below follows a brief description of all the proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The organization of HPV genome. Reprinted with permission  
 
 
E1 and E2 proteins are transcription factors, essential for HPV replication,200 by forming a 
complex and bind to the viral origin of replication located on the LCR.201 E1 and E2 also recruit 
host polymerase for viral gene transcription 202 and E2 regulates and represses the transcription 
of early genes by preventing host factors from binding to viral promoters.203 E2 is often deleted 
in advanced cervical cancer, where the transcription of E6 and E7 proteins is deregulated.204  
 
E4 protein is produced from splicing mRNA of E1.193 The role of E4 is not yet fully 
understood. Speculations suggest that it has a role to create favorable conditions for viral 
maturation in the productive HPV infection.193 Research has shown that E4 is common in warts, 
e.g. infection with HPV 1193 and that the cytoskeleton in cell cultures can collapse due to  
interaction with E4 from HPV 16.205  
 
E5 protein is usually absent in invasive cervical cancer but present in low-grade epithelial 
neoplasia, supporting the speculation of E5 playing a role early in HPV infection. The protein 
also seems to enrich the mitogen activity-protein pathway (MAP) resulting in an increased 
response to growth stimulating factors.206  
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E6 protein is one of the two oncoproteins present in the HPV particle. It consists of 160 amino 
acids207 and the overexpression of E6 has been shown to facilitate oncogenesis by interfering 
with the host cell in several ways, briefly:  
¥ E6 binds and degrades p53208 inhibiting growth arrest and apoptosis after DNA 
damage209 and resulting in cell proliferation and tumor development.210  
¥ E6 can also, independently from p53, prevent apoptosis and contribute to cell 
proliferation by interacting with the pro-apoptotic bax protein and tumor necrosis 
factor 1 (TNFR1).211  
¥ E6 immortalizes the host cell by activating transcription of human telomerase reverse 
transcriptase (hTERT).212  
¥ E6 contributes to cellular transformation by degrading cellular proteins containing a 
so-called PDZ domain213 involved in the formation of cell-to-cell adherence, cellular 
polarity and cell signaling. By losing these abilities, the cell transforms and becomes 
carcinogenic.214 215 E6 can also contribute to anchor-independent and invasive tumor 
growth by degrading the PDZ domain protein called PTPN13.216 The ability to bind 
proteins containing the PDZ domain is exclusive to HR HPV; LR HPV does not have 
the PDZ-binding motif.217  
¥ E6 has also been suggested to reduce immune response by down regulation 
transcription of inerleukin-8218 and modulate G protein signaling.219  
 
E7 protein is the second of the two oncogenes present in the HPV particle. It consists of 100 
amino acids207 and overexpression of E7 has been shown to facilitate oncogenesis by interfering 
with the host cell in several ways, briefly:  
¥ E7 induces enhanced cellular proliferation in several ways, the most famous being by 
interaction with retinoblastoma protein (pRb).220 This process also contributes to 
overexpression of p16 through loss of feedback inhibition. P16 is considered to be a 
surrogate biomarker for transforming HPV infection, is correlated to degree of 
dysplasia221 and found in almost all cervical cancers.222 Overexpression of p16 is 
mainly seen in HR and pHR HPV types 16, 18, 31, 33, 52 and 58.223  
¥ E7 enables autocrine growth in HPV positive lung tumors by upregulating expression 
of interleukin 6 (IL-6).224  
¥ E7 contributes to the inactivation of the immune system by interacting with 
interferon regulatory protein 1 (IRP1) and interferon-α (IFN-α).225  
¥ E7 can induce anchoring-independent cell growth by targeting the p600 protein, a 
member of the pRb family.226  
 
L1 and L2 proteins are structural proteins forming the viral icosahedral capsid.227 The open 
frame region (OFR) of the L1 gene is also used to define different HPV types. The gene 
sequence of the ORF has to differ at least 10% for it to be called a new subtype of HPV.198  
 
 
HPV detection methods 
 
Traditionally, direct probe assay (Southern blot) has been used as a “golden standard” for 
detecting a specific DNA sequence, i.e. HPV DNA, but due to significant time consumption, 
the need for large DNA samples, and the lack of advantages compared to more modern 
methods,228 229 the most frequently used assays for HPV detection today are signal amplification 
Hybrid Capsid 2 (HC2) and polymerase chain reaction (PCR).230  
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Hybrid capture 2 
 
Hybrid capture 2 (HC2) is a signal amplification method based on type-specific RNA probes 
that hybridize to a distinct DNA region. The produced RNA-DNA hybrid attaches to a micro 
plate coated with monoclonal antibodies and then another monoclonal antibody conjugated to 
alkaline phosphatase will attach to the complex. Detection of HPV occurs when 
chemiluminescent substrate is spliced by alkaline phosphatase, producing light measured in a 
luminometer as relative light units (RLU).  
Sensitivity of Hybrid Capture 2 is lower than for PCR (95.6 versus 100%),231 and HPV is 
detected when 500-5,000 virus genomes are present in one cell.232  
 
Polymerase Chain reaction (PCR) 
 
The PCR assay is based on amplification of a specific DNA sequence identified through 
primers, i.e. a chain of complementary oligonucleotides binding to the DNA sequence of 
interest. For detection of a wide range of HPV types, primers target the OFR of the L1 gene, a 
highly conserved region common in most HPV types. There are several different HPV primers; 
in this thesis the highly evaluated broad-spectrum BGP5+ and BGP6+ primers were used.233  
The PCR procedure is repeated in approximately 45 cycles and starts with denaturing DNA 
(94°C); primers will attach in the annealing stage (40°C) and the specific DNA sequence is 
transcribed using the Taq polymerase (72°C).  
Various methods are used for HPV genotyping, where sequencing using type specific PCR and 
multiplex with Luminex are two methods that are highly validated.234 In this thesis the latter 
method will be used since it is a highly validated method recommended by the WHO group.235  
The multiplex HPV genotyping with Luminex is based on hybrids of oligonucleotide probes, 
coupled to internally dyed polystyrene beads marked with fluorescence which attach to specific 
sites on the amplified HPV DNA. A Luminex reader containing two different lasers is used to 
measure the internal color of the HPV type specific beads and the quantity of fluorescence, 
measured in median fluorescence intensity.234 There are more than 100 different beads available 
and the Luminex is capable of measuring more than 100 types of HPV at the same time.234 
Multiplex HPV genotyping with Luminex has a high sensitivity and specificity compared to 
other methods, although its greatest advantage is that it enables accurate testing of multiple 
HPV types (more than 100) at the same time.234 235 
 
 
Detection of p16INK4a by immunohistochemistry  
 
Detection of HPV DNA in tumor material is usually not enough to demonstrate a causal 
relationship between the HPV and the type of cancer studied; viral/biological activity is also 
needed. In order to assess biological activity of HPV in tumors, p16INK4a, a surrogate marker for 
HPV activity,236 237 can be measured using immunohistochemistry. Tumor material is sectioned 
and stained with a monoclonal antibody against p16 and the slides are graded through 
microscopic examination. This method has a high sensitivity (100%), when combined with a 
PCR method and a low specificity (79%),238 due to HPV independent pathways for 
carcinogenesis and overexpression of p16.  
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Human papillomavirus and cancer  
 
General 
 
Most HPV infections are cleared within two years after outbreak, however, a small fraction 
does for unknown reasons proceed from productive to transforming infection. The carcinogenic 
steps of HPV infection from precancerous dysplastic lesions to invasive cancer, have been 
studied in detail for cervical cancer. Initially, the virus implants its genome into the host cell 
enabling E2 production which then suppresses the expression of E6 and E7 proteins. The next 
step is not quite clear, although a deletion of E2 occurs resulting in an unregulated expression of 
E6 and E7 which then creates cellular transformation/proliferation, interference with host cell 
immune system and other effects mentioned above;239 240 the cancer development then becomes 
a fact. HPV has been linked to several types of cancer; the text below contains a brief 
description.  
 
 
Cervical cancer 
 
Cervical cancer is the second most common type of cancer in women globally, with 80% of 
cases occurring in developing countries.1 Numerous studies have investigated the causal 
relationship between HPV and cervical cancer and the current knowledge of HPV is mainly 
derived from this research. About 95% of cervical squamous cell carcinomas contain HPV 
DNA, HPV 16 being the dominating type and HPV 18 in the case of cervical 
adenocarcinomas.199 241  
 
 
Oropharyngeal cancer 
 
In 2007, HPV was classified as a risk factor for oropharyngeal squamous cell carcinoma 
according to the International Agency for Research on Cancer (IARC).242 243 The causal 
relationship had already been suggested in 1975, when women with cervical carcinoma had a 5-
6 fold elevated risk of developing a second cancer in the oral cavity.244 Similar results were also 
seen in 1999, when patients with anogenital cancers were shown to have a 4.3-fold increased 
risk of tonsillar cancer.245  
The frequency of HPV DNA in head and neck squamous cell carcinoma varies largely with 
anatomic site; 246 the highest prevalence of high risk HPV DNA is found in oropharyngeal 
cancer (25 to 60%).247 When comparing patients with HPV-positive and negative 
oropharyngeal tumors, positive patients are characterized by their younger age at the time of 
diagnosis and their non-smoking status,243 and importantly, HPV has been established as an 
independent prognostic factor for survival.246 248 249 243 250 The incidence of oropharyngeal cancer 
has rapidly increased during the last three decades, by 3.9 times in tonsillar and 2.1 times in 
tongue-based squamous cell carcinoma.1 251 252 The increased incidence might be explained by a 
rise in HPV infections in the oral cavity caused by a change in sexual habits, alongside an 
increased number of vaginal or oral sexual partners.253  
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Other HPV related cancers  
 
HPV has also been associated with anogenital cancers; 50% of vulvar,254 30-65% of penile255 
and as much as 90% of vaginal cancers197 254 contain HPV DNA, particularly of the HPV 16 
type.255 As well as in oropharyngeal tumors, HPV-positive vulvar and penile cancers tend to 
have a better prognosis and sexual behavior is a strong risk factor.255 HPV has also been 
suggested as a causal factor for squamous cell carcinoma of the skin, although the results are 
contradicting and more research is needed.247  
 
 
HPV and esophageal cancer 
 
An association between HPV and esophageal squamous cell carcinoma was initially suggested 
in 1982, when morphological similarities between HPV induced lesions in the genital tract, i.e. 
condyloma, and esophageal squamous cell carcinoma were discovered.256 Since then, several 
studies have been conducted and the results were summarized in a review article in 2002, where 
a range of 0 to 70% of tumors were positive for HPV infection.257 The great diversity of results 
was mainly explained by the different laboratory techniques used and the different geographic 
regions tested. The use of a filter in situ hybridization (FISH) and in situ hybridization 
generated a much higher incidence of HPV compared to PCR and the incidence of HPV was 
higher in high risk areas for esophageal cancer.257  
Since this review article was published, the diversity of results have continued; studies from 
high-risk regions in China, South Africa and Iran indicate a prevalence of 37 to 77% of HPV 
DNA in esophageal tumors258-261 although some studies show completely contradicting 
results.262-264 The prevalence of HPV DNA in Europe varies between 16 and 28%265-267 and no 
favorable prognostic effect is found in HPV positive esophageal tumors.267 No study has, to our 
knowledge, addressed tumor localization as a primary endpoint, although a Swedish study 
included tumor location when studying survival.267  
To summarize, there is still confusion as to whether HPV is a causal factor for esophageal 
squamous cell carcinoma.  
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AIM       
 
 
The general aim of this thesis was to advance our understanding of the etiological factors 
behind esophageal cancer.  
 
The specific aims are:  
 
¥ To clarify as to whether the established etiological factors for esophageal and cardia 
adenocarcinoma exist to a different extent in women and men.  
 
¥ To clarify as to whether the population prevalence of known risk factors for 
esophageal adenocarcinoma is higher in the UK as opposed to in Sweden.  
 
¥ To clarify potential differences between antireflux operated patients who do or do not 
develop esophageal adenocarcinoma after such surgery.  
 
¥ To determine as to whether HPV is more strongly associated with squamous cell 
carcinoma of the proximal esophagus as opposed to the distal esophagus.  
 
 
 
 
  
S 
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MATERIALS AND METHODS    
 
 
Data for this thesis has been obtained from several databases; an overview of methods used is 
presented in Table 2 below.  
 
Table 2. An overview of material and methods used in this thesis.  
 
  
Paper I Paper II Paper III Paper IV 
Design Population-based case-
control study 
Population-based cross-
sectional study 
Population-based case-
control study nested 
within an antireflux 
cohort 
Population-based case-
control study 
Data source  Swedish Esophageal 
and Cardia Cancer-
study 
Bristol Helicobacter 
Project-study, Reference 
Population-study 
Patient Register Cancer 
Register 
Cancer Register 
Year 1994-1997 1996-1999, 2008 1965-2006 1999-2006 
Participants  451 cases, 816 controls 3633 (English) 1483 
(Swedish) 
55 cases, 240 controls 20 cases, 184 controls 
Study exposure Gastroesophageal reflux 
symptoms, high BMI, 
tobacco smoking, high 
intake of fruit and 
vegetables, infection 
with H. Pylori 
Gastroesophageal reflux 
symptoms, 
overweight/obesity, 
tobacco smoking 
Recurrent 
gastroesophageal reflux, 
high BMI, tobacco 
smoking, different types 
of antireflux surgery 
HPV infection 
Outcome Esophageal/cardia 
adenocarcinoma 
English or Swedish 
outcome 
Esophageal/cardia 
adenocarcinoma 
Tumor located in the 
proximal part of the 
esophagus 
Statistical analysis Unconditional logistic 
regression 
Logistic regression Conditional logistic 
regression 
Fischer exact test, 
logistic regression 
Estimate Odds ratio Odds ratio  Odds ratio Odds ratio 
Matching Age, sex Matching for age and 
sex to cases of 
esophageal 
adenocarcinoma was 
made when sampling in 
the Swedish population 
- - 
Confounders Age, sex, educational 
level, alcohol use, 
gastroesophageal reflux 
symptoms, BMI, 
tobacco smoking, high 
intake of fruit and 
vegetables, H. Pylori 
infection 
Age, sex, educational 
level, gastroesophageal 
reflux symptoms, BMI, 
tobacco smoking 
Age, sex, recurrent 
gastroesophageal reflux, 
BMI, tobacco smoking 
and type of antireflux 
surgery 
Age, sex and tumor 
differentiation 
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MATERIALS AND METHODS    
 
 
Data for this thesis a  been obtained from several dat bases; n overview of methods used is 
presented i  Table 2 elow.  
 
Table 2. An overview of material and methods use  in this thesis.  
 
  
Paper I Paper II Paper III Paper IV 
Design Populati n-b sed case-
control study 
Populati n-b sed cro s-
sectional study 
Populati n-b sed case-
control study nested 
within an antireflux 
cohort 
Populati n-b sed case-
control study 
Data source  Swedish Esop ageal 
and Cardia ancer-
study 
Bristol Helicobacter 
Project-study, Reference 
Populati n-study 
Patient Register Cancer 
R gister 
Cancer Register 
Year 1994-19 7 1996-19 , 2008 1965-200  1999-2006 
Particip nts  451 cases, 816 controls 3633 (English) 1483 
(Swedish) 
55 cases, 240 controls 20 cases, 184 controls 
Study exposure Gastroesophageal reflux 
symptoms, high BMI, 
tobacco smoking, high 
intake of fruit and 
vegetables, infectio  
with H. Pylori 
Gastroesophageal reflux 
symptoms, 
overweight/obesity, 
tobacco smoking 
Recurrent 
gastroesophageal reflux, 
high BMI, tobacco 
smoking, different typ s 
of antireflux surgery 
HPV infectio  
Outcome Esophageal/c rdia 
adenoc rcinoma 
English or Swedish 
outcome 
Esophageal/c rdia 
adenoc rcinoma 
Tumor located in the 
proximal part of the 
esophagus 
Statistical analysis Unconditional logistic 
regression 
Logistic regression Conditional logistic 
regression 
Fischer exact t st, 
logistic regression 
Estimate Odds ratio Odds ratio  Odds ratio Odds ratio 
Matching Age, sex Matching for a e and 
sex to cases of 
esophageal 
adenoc rcinoma was 
made when sampling in 
the Swedish populati n 
- - 
Confounders Age, sex, ducational 
level, alcohol use, 
gastroesophageal reflux 
symptoms, BMI, 
tobacco smoking, high 
intake of fruit and 
vegetables, H. Pylori 
infectio  
Age, sex, ducational 
level, gastroesophageal 
reflux symptoms, BMI, 
tobacco smoking 
Age, sex, recurrent 
gastroesophageal reflux, 
BMI, tobacco smoking 
and type of antireflux 
surgery 
Age, sex and tumor 
differentiation 
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Data source  
 
 
The Swedish Esophageal and Cardia Cancer study  
 
The Swedish Esophageal and Cardia Cancer (SECC) study has been described in detail 
elsewhere.5 In brief, the SECC-study was conducted in Sweden between December 1, 1994 and 
December 31, 1997 with the primary aim to identify risk factors for esophageal and cardia 
adenocarcinoma. All Swedish residents below the age of 80 years were eligible for 
participation. Patients newly diagnosed with esophageal or cardia adenocarcinoma were 
identified as cases by means of collaboration between all general and thoracic surgical 
departments, as well as departments of otorhinolaryngology, oncology and pathology 
throughout Sweden. Study protocol and posters were placed at all gastroenterology and 
endoscopy units and collaborations with six regional tumor registers were established in order 
to ensure that all cases of esophageal cancer were identified. A newsletter was produced and 
sent out regularly (every 3 months) to keep all collaborators updated about study procedures 
and progressions.  
 
Tumor classification 
 
Specific study protocols and color posters were developed in order to ensure correct tumor 
location and histological classification. Diagnosis was individually determined for all cases by 
summarizing findings from four different disciplines:  
 
¥ Endoscopy: obtaining tumor location/borders and biopsies by means of endoscopic 
examination at least once in all cases.  
¥ Radiology: ascertaining tumor location by means of CT scan and endoscopic 
ultrasound.  
¥ Surgery: if tumors were resected or if explorative surgery was performed, tumor 
borders and center were carefully recorded according to a specific study protocol.  
¥ Pathology: biopsies and surgical specimens were sectioned and histologically 
classified according to a specific study protocol, furthermore 97% of all tumors were 
re-examined by a single experienced pathologist (Anders Lindgren).  
 
In order to distinguish between esophageal and gastric cardia tumors (data was collected before 
Siewert’s definitions were published),20 gastric cardia tumors were defined as located 2 cm 
above or 3 cm below the esophagogastric junction268 and all patients with BE were defined as 
having esophageal adenocarcinoma. In ambiguous cases, a panel of investigators with 
experience in all four disciplines evaluated the case and agreed upon a final tumor 
classification.  
For every case, four or five randomly selected controls were continuously obtained from the 
Swedish Total Population Register. Controls were frequency matched from a ten-year age and 
gender strata in order to mimic sex and age distributions of cases. Both cases and controls 
underwent face-to-face interviews as described in detail below.  
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Bristol Helicobacter Project 
 
The Bristol Helicobacter Project (BHP) was initially conducted as a double-blind, placebo-
controlled randomized clinical trial aiming at investigating the impact of H. pylori in patients 
with uninvestigated dysphagia.269 Data was collected between July 1996 and January 1999 from 
a local English register, covering seven primary care centers in Bristol and surrounding areas. 
All residents aged 29-59 years were eligible to be contacted by mail and asked to participate in 
the study; non-responders were contacted by telephone after three weeks.  
Study participants were asked to fill out a questionnaire (further described below in paper II), 
measure their height and weight and perform a urea breath test for H. pylori at their general 
practitioners office, after which they were randomly assigned Helicobacter eradication therapy 
or a placebo. The initial questionnaire is included in this thesis.  
 
 
The Reference Population Study 
 
The Reference Population (RP) study is a random sample of the adult Swedish population, 
collected between April and June 2008. All Swedish residents aged 40 to 59 years were eligible 
for the study, and were randomly selected based on age, sex and geographic distribution of 
esophageal adenocarcinoma cases reported in the Swedish Cancer Register in 2006. 
Questionnaires (identical to BHP) were mailed out to all participants and both randomization 
and data collected was performed by Statistics Sweden, using the nationwide and highly 
complete Swedish Register of the Total Population.  
 
 
The Swedish Cancer Register 
 
The Swedish Cancer Register, held by the National Board of Health and Welfare, contains 
virtually all cancer cases diagnosed in Sweden since 1958. Clinicians and pathologists are 
legally obligated to report the occurrence of new cancer cases to their regional cancer registrar, 
who then forwards the information to the nationwide Swedish Cancer Register.270 Clinicians 
report the location of all tumors detected, regardless of biopsy specimen verification, and 
pathologists report histologically confirmed cancers, including those detected at autopsy.270 The 
register is coded according to the International Classification of Disease for Oncology (ICD-
O)271 and patients are identified through a unique ten-digit personal identity number.272  
The comprehensiveness of the Swedish Cancer Register is overall 96.3%,273 and 98% 
respectively for esophageal and cardia cancers, although the latter condition was included in 
non-cardia gastric cancer only until 1970.274 The Swedish Cancer Register is considered to have 
a high validity when compared to other registers in northern Europe.273  
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The Swedish Patient Register 
 
The Swedish Patient Register, previously known as the Swedish In-Patient Register and the 
Hospital Discharge Register, contains diagnoses (maximum of six to eight per care episode) 
and surgical procedures (maximum of six to twelve per care episode) from the in-patient care of 
Swedish residents.275 The register was established in 1964 and covered 60% of the Swedish 
population in 1969, 85% in 1983 and the entire population (100%) from 1987 onwards.275 
Diagnosis and surgical procedures from out-patient clinics have been included since 1997, 
although specialized out-patient care was not included until 2001.275 The register is coded 
according to WHO’s International Classification of Disease271 and patients are identified 
through their personal identity number.272 The completeness of the Swedish Patient Register is 
98% for all hospitalizations and main diagnoses are present for 99% of all hospital 
admissions.275  
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Paper I – Sex-specific risk factor profile in oesophageal adenocarcinoma 
 
 
Hypothesis 
 
Due to the unexplained male predominance in esophageal and cardia adenocarcinoma (3-
10:1),11 20 44 we hypothesized that the established etiological factors are different in women and 
men, with risk factors being stronger in men and protective factors being stronger in women.  
 
 
Design  
 
This was a population-based case-control study comparing the distribution and strength of 
known risk factors for esophageal and cardia adenocarcinoma among women and men. Cases 
and controls, matched for age and sex, were identified from the SECC-study conducted in 
Sweden between December 1, 1994 and December 31, 1997.  
 
 
Assessment of study exposure  
 
Information about most study exposures (gastroesophageal reflux symptoms, height and 
weight, tobacco smoking and intake of fruit and vegetables) and potential confounders (alcohol 
consumption, socioeconomic status/educational level) were in both cases and controls collected 
in face-to-face interviews within five weeks after diagnosis. Interviewers were unable to be 
blinded as to the study outcome; however, they were unaware of the study hypothesis and 
trained to treat cases and controls equally. In order to avoid reverse causation, all questions 
were asked about study exposure and potential confounders during the last five years prior to 
interview. Infection with H. pylori was detected through the collection of venous blood taken 
from cases during their initial hospital stay and controls were asked to leave a blood sample at 
their local health center. 
 
Gastroesophageal reflux was defined as recurrent heartburn or regurgitation at least once a 
week for more than a year, and was measured in frequency, severity and duration. A reflux 
symptom score was generated based on frequency (once a week=0 points, 2-6 times a week=1 
point, 7-15 times a week=2 points, more than 15 times a week=3 points) and characteristics of 
reflux symptoms (heartburn only=1 point, regurgitation only=1 point, heartburn and 
regurgitation combined=1.5 points, nightly symptoms=2 points). BMI (<22.0, 22.0-24.9, >24.9) 
was calculated from height and weight at the age of 20, twenty years before the interview and 
adult extreme values (minimum and maximum weight). Tobacco smoking was defined by 
means of frequency, duration and number of years since smoking cessation. Smoking status 
was defined as current, previous (stopped smoking 2 or more years before the study) or never 
smoker. Pack year was calculated as the number of cigarette packets (40 cigarettes) per day 
multiplied by the number of smoking years. Intake of fruit and vegetables was measured with a 
previously evaluated food-frequency questionnaire.276 Questions were asked about the average 
intake of 63 food and beverage items 20 years prior to the interview. Fruits included citrus 
fruits, fruit juice, apple and pears, covering 86.9% of the total fruit types consumed in Sweden 
(Swedish Board of Agriculture 1989). Vegetables included allium vegetable types, beets, 
broccoli, cabbage, cauliflower, carrots, lettuce, potatoes, spinach and tomatoes, covering 96.5% 
of the total vegetables consumed in Sweden (Swedish Board of Agriculture 1989). The variable 
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used for fruit and vegetables was constructed using quartiles from the total intake in controls; 
high corresponded to the 4th quartile, medium to the 2nd and 3rd quartile and low to the 1st 
quartile. Infection with H. pylori was detected through enzyme-linked immunosorbent assay 
(ELISA) (Pyloriset EIA-G; Orion Diagnostica, Espoo, Finland) with 98% sensitivity and 85% 
specificity277 which measured immunoglobin (IgG) antibodies against HP-CSAs in serum 
(positive/negative). Antibodies against CagA (positive/negative) were detected with an 
immunoblot assay (Helicoblot 2.1; Genelabs Diagnostics, Singapore). All investigators were 
blinded to participants’ case-control status.  
 
 
Statistical analysis  
 
Unconditional logistic regression stratified by sex, was used to calculate estimated odds ratios 
(OR) with 95% confidence intervals (CI) for risk factors in women and men. Adjustment for 
potential confounding factors: age (<49, 50-59, 60-69, 70-79 years), educational level (0-9, 10-
12, ≥13 years) and alcohol use (yes or no), gastroesophageal reflux, BMI, tobacco smoking, 
intake of fruit and vegetables and H. pylori infection was performed in a multivariable model. 
Esophageal or cardia adenocarcinoma was the outcome and the study exposure included 
gastroesophageal reflux symptoms, BMI, tobacco smoking, intake of fruit and vegetables and 
infection with H. pylori. Separate analyses were also performed for esophageal and cardia 
adenocarcinoma.  
 
 
 
Paper II – Increased prevalence of reflux and obesity in the United Kingdom 
compared with Sweden: a potential explanation for the difference in incidence of 
esophageal adenocarcinoma 
 
 
Hypothesis 
 
Due to the much higher incidence of esophageal adenocarcinoma in England compared to 
Sweden, we hypothesized that the English population has a higher prevalence of established 
risk factors for esophageal adenocarcinoma, i.e. gastroesophageal reflux symptoms, high BMI, 
and tobacco smoking. 
 
 
Design  
 
This was a population-based cross-sectional study comparing population prevalence of risk 
factors for esophageal adenocarcinoma in random samples from England and Sweden. Data 
was collected from the BPH and the RP study.  
 
 
Assessment of study exposures 
 
Study exposures were assessed through self-administrated questionnaires, initially developed 
for the BPH. Most questions were extracted from a previously validated questionnaire used in a 
large British study in 1996.278 Great efforts were made to ensure that the English and Swedish 
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questionnaires were linguistically identical. Three native Swedes independently translated the 
questionnaire into Swedish and agreed on a final version. Compatibility was evaluated through 
a bilingual person (native English), translating the questionnaire back into English and 
comparing it to the original version, with very accurate results. Before the Swedish 
questionnaire was sent out it was tested on twenty Swedes so as to evaluate comprehensibility.  
Questions included (1) demography: age, sex and educational level, and (2) risk factors for 
esophageal adenocarcinoma: frequency and severity of gastroesophageal reflux symptoms 
(heartburn and regurgitation), adult height and weight, and tobacco smoking status.   
GERD was defined according to the Montreal definition107 as heartburn and regurgitation 
occurring at least once a week or as troublesome for the patient,107 and was assessed through 
frequency (not at all in the last three months, less than once a month, at least once a month, at 
least once a week, everyday) and severity (no problem at all, a mild problem, a moderate 
problem, a severe problem, a very severe problem), using a five point Likert scale.279 BMI was 
categorized according to the WHO definitions (<18.5, 18.5-24.9, 25.0-30.0, >30.0).153 Tobacco 
smoking was defined as current (smoked during the last three months), previous (not smoked 
for the last three months) and never (never smoked one or more cigarettes a day for one year or 
more).  
The most important difference in data collection between the two populations was the 
assessment of height and weight. A nurse measured height and weight in the English sample, 
whereas it was self-reported in the Swedish sample.  
 
 
Statistical analysis 
 
Unconditional logistic regression was used to calculate OR with 95% CI and p-values as an 
effect index comparing the prevalence of gastroesophageal reflux symptoms, BMI and tobacco 
smoking status, in the two populations. Distribution of age, sex and educational level was 
different for the populations and two multivariable models were performed using the Swedish 
population as reference. Model one was adjusted for age (40-44, 45-49, 50-54, 55-59 years), 
sex and educational level (0-9, 10-12, ≥13 years) and model two was further adjusted for 
gastroesophageal reflux symptoms, BMI and smoking status. The primary outcome was 
English or Swedish origin and study exposure was gastroesophageal reflux symptoms, BMI and 
tobacco smoking.  
Previous studies show that patients with a combination of gastroesophageal reflux symptoms 
and obesity have a considerably increased risk of esophageal adenocarcinoma.7 To investigate 
as to whether a combination of risk factors for esophageal adenocarcinoma was more common 
in the English population, study exposures, gastroesophageal reflux symptoms (at least once a 
week and more), BMI (overweight and obesity) and tobacco smoking status (never/ever) were 
combined and compared in the two populations in the same way as mentioned above.  
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Paper III – Risk factors for esophageal adenocarcinoma after antireflux surgery 
 
 
Hypothesis 
 
Due to the previously observed absence of a cancer protective effect from antireflux surgery, 
we hypothesized that recurrent reflux or high exposure to other well established risk factors for 
esophageal or cardia adenocarcinoma are overrepresented among patients who, despite 
antireflux surgery, develop cancer. 
 
 
Design  
 
This was a population-based case-control study nested within a cohort of all antireflux operated 
patients in Sweden, between 1965 and 2006. Cases were those who developed cancer at least 
five years after surgery and were identified by means of linkage between the Swedish Patient 
Register and the Swedish Cancer Register. For every case five randomly selected controls were 
selected from the antireflux cohort, matched in gender, age and calendar year of antireflux 
surgery. Both cases and controls were operated with severe GERD as indication.  
 
 
Assessment of study exposure 
 
Medical records were collected throughout Sweden and examined by one reviewer (Hedvig 
Löfdahl) who was blinded as to case-control status. To avoid using medical records from the 
point of identification of esophageal adenocarcinoma, only records from the primary antireflux 
operation and up to 2 years after surgery were obtained. Collected variables included sex, age at 
antireflux operation (<50, 50-59, >59 years) and study exposure including recurrent 
gastroesophageal reflux symptoms after surgery (yes or no, including medically or surgically 
treated symptoms), high BMI (<25 or ≥25), tobacco smoking (never or ever) and type of 
antireflux surgery (Nissen, Toupét or other type).  
 
 
Statistical analysis  
 
Relative risk, addressed as OR with 95% CI was calculated using conditional logistic 
regression. Two multivariable models were used adjusting for sex and age of antireflux surgery 
in the first model and recurrent reflux, BMI, tobacco smoking, and type of operation 
additionally in the second model. Missing data was grouped into separate categories. The 
primary outcome was esophageal or cardia adenocarcinoma and study exposures included 
recurrence of gastroesophageal reflux symptoms after surgery, high BMI, tobacco smoking and 
type of antireflux surgery.  
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Paper IV – Infection with human papillomavirus (HPV) in relation to site of 
squamous cell carcinoma of the esophagus 
 
 
Hypothesis 
 
Due to the fact that previous studies showed diverse results of HPV as a risk factor for 
esophageal cancer and because of HPV’s association with oropharyngeal cancer,242 we 
hypothesized that tumor location might be connected to presence of HPV infection and that 
squamous cell carcinomas of the proximal esophagus are positive for HPV infection to a greater 
extent than tumors of the middle or distal esophagus.  
 
 
Design 
 
This was a population-based case-control study including all patients diagnosed with 
esophageal squamous cell carcinoma in the Stockholm County between 1999 and 2006. Cases 
and controls were identified through the Swedish Cancer Register using the unique personal 
identity number.272 Cases represented patients with a higher location of their tumor, whereas 
controls were patients with a distal tumor location.  
 
 
Assessment of study exposure  
 
Age (<60, 60-70 or >70 years) and tumor location data were obtained from medical records. 
The tumor site was examined by one reviewer (Hedvig Löfdahl), blinded to case-control status. 
Patients were classified according to the 6th edition of the ASCC tumor classification,14 as 
proximal (15-24 cm from the incisors), middle (25-30 cm from the incisors), or distal tumors 
(30-45 cm from the incisors).  
 
 
Detection of human papilloma virus  
 
DNA extraction and HPV genotyping were performed on histologically confirmed paraffin 
embedded endoscopic biopsies of esophageal squamous cell carcinomas, obtained before 
neoplastic treatment. Only endoscopic biopsies were eligible in order to avoid detection bias, 
since surgical specimens from tumor resection are more commonly used on tumors located in 
the distal esophagus making it easier to detect HPV infection. To avoid tumor misclassification, 
a single pathologist re-examined and graded tumor differentiation (high, middle and low) for all 
biopsy specimens.  
 
Formalin-fixated paraffin embedded biopsies was sectioned on glass (4 x 15 µm). Macro-
dissection was performed to make sure that predominantly tumor material was present in the 
analysis, and to minimize the risk of contamination, blanks were added after every 5th sample 
and treated in the same way as real samples during slicing and macro-dissection.  
A High Pure RNA Paraffin Kit (Roche’s) without DNAse was used for DNA extraction. PCR 
was performed by adding 10 µl of DNA sample and 40 µl of reaction mixture, containing 
broad-spectrum GP5+/6+ primers (BGP5+/BGP6+) to the Qiagen Multiplex PCR Master Mix 
(Qiagen, Hilden, Germany).233 Amplification was made in 40 cycles, with a temperature of 
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38°C for 90 seconds. HPV genotyping was conducted with Luminex234 280 together with a 
Multimetrix kit (Heidelberg, Germany) analyzing 24 HPV types, including 15 HR types (16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), 3 putative HR types (26, 53, 66) and 6 LR 
types (6, 11, 42, 43, 44, 70).199 Hybridization of PCR products (10 µl) and Luminex beads (40 
µl) together with the subsequent steps were performed using standard methods. The samples 
were analyzed using the Luminex 100 analyzer (BioRad Laboratories, Hercules, USA) with the 
cut-off limits proposed by the manufacturer.  
 
Detection of p16INK4a by immunohistochemistry  
 
Biological activity of HPV in tumors was measured using immunohistochemistry for 
expression of p16INK4a, a surrogate marker for HPV activity.236 237 Biopsies were sectioned and 
stained using the monoclonal antibody p16 (delusion 1:200, clone JC8, Santa Cruz 
Biotechnology, INC) and a standard streptavidin-biotin peroxidase method. Almost all HPV 
positive cases and six HPV negative controls per each case were evaluated for p16 by a single 
pathologist who graded samples according to nucleus staining in four categories (negative, <5% 
or weak nuclear staining, 5-30% and >30%) and used two categories (negative/<5% or weak 
staining, or >5 %) in the statistical analysis.  
 
 
Statistical analysis 
 
A Fischer exact test was used to identify predictors of HPV-positive tumors, with a p-value 
below 0.05 considered as statistically significant. Odds ratios (OR) with 95% confidence 
intervals (CI) were calculated using unconditional logistic regression to determine relative risk 
of different tumor locations when exposed to HPV infection. Multivariable modeling was used 
to adjust for potential confounders (age, gender, and tumor differentiation). Any missing data 
was grouped into a separate category. The primary outcome was squamous cell carcinoma 
located in the proximal esophagus and the study exposure was HPV infection.  
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RESULTS      
 
 
Paper I – Sex-specific risk factor profile in oesophageal adenocarcinoma 
 
 
In this study, 451 (85%) cases of esophageal or cardia adenocarcinoma and 816 (72%) controls 
participated in the interviews. Among the cases, 63 (14%) were women and 388 (86%) were 
men, resulting in a male to female ratio of 7:1. The level of education was generally lower in 
women compared to men and in the cases compared to the controls (data not shown).  
 
 
Risk factors in women and men  
 
All established risk factors, i.e. gastroesophageal reflux symptoms, high BMI, and tobacco 
smoking, were associated with an increased risk of esophageal or cardia adenocarcinoma in 
both men and women (Table 3).  
 
 
Table 3. Risk factors for esophageal and cardia adenocarcinoma in women versus men, expressed in OR with 
95% CI.  
 
Variables 
Women Men 
Controls Cases OR* Controls Cases OR* 
N = 140 (%)  N = 63 (%) (95% CI) N = 676 (%) 
N = 388 
(%) (95% CI)  
       Reflux (at least weekly 5 years or more prior to 
interview)     
       No 17 (12) 25 (40) 1.0 (reference) 118 (17)  163 (42) 1.0 (reference) 
Yes 123 (88) 38 (60)  4.6 (2.0-10.5) 558 (83) 225 (58) 3.4 (2.5-4.6) 
       BMI (20 years before interview)      
       <22 56 (40)  12 (19) 1.0 (reference) 151 (22) 45 (12) 1.0 (reference) 
22.0-24.9 55 (39) 25 (40) 2.4 (0.9-6.0) 311 (46) 143 (37) 1.5 (1.0-2.3) 
25.0-29.9 22 (16) 16 (25) 4.3 (1.4-13.1)) 196 (29) 164 (42) 2.7 (1.8-4.1) 
≥30.0 7 (5)  10 (16) 10.3 (2.6-42.3) 18 (3) 36 (9) 5.4 (2.6-10.8) 
       Cigarette smoking status (2 years before interview) 
       Never 90 (64)  29 (46)  1.0 (reference) 233 (35) 71 (18) 1.0 (reference) 
Previous 28 (20)  13 (21) 1.9 (0.7-5.1) 285 (42) 200 (52)  2.3 (1.6-3.3) 
Current 22 (16) 21 (33) 5.3 (2.0-14.1) 158 (23) 117 (30) 2.8 (1.9-4.2) 
              
* Adjustments were made for age, educational level, alcohol use, BMI, cigarette smoking, intake of fruit and 
vegetables, and H. pylori infection.  
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RESULTS      
 
 
Paper I – Sex-specific r sk factor pr file in oesophageal adenocarcinoma 
 
 
In this study, 451 (8 %) cases of ophageal or cardia denocarcinoma and 816 (72%) controls 
participa ed in the interviews. Among the cases, 63 (14%) were omen and 388 (86%) were 
men, resulting in a male to f male ratio of 7:1. The level of ducation was generally lower in 
women compared to men and in the cases ompared to the controls (data not shown).  
 
 
Risk factors in women and men  
 
All establi hed risk factors, i.e. gastroesophageal reflux sympto s, high BMI, and tobacc  
smoking, were associated with an increased ri k of es phageal or cardia a enocarcinoma in 
both men and women (Table 3).  
 
 
Table 3. Risk factors for esophageal nd c rdia denocarcinoma in women versus men, expressed in OR with 
95% CI.  
 
Variables 
Women Men 
Controls Cases OR* Controls Cases OR* 
N = 140 (%)  N = 63 (%) (95% CI) N = 676 (%) 
N = 388 
(%) (95% CI)  
       Reflux (at least weekly 5 years or more prior to 
interview)     
       No 17 (12) 25 (40) 1.0 (reference) 118 (17)  163 (42) 1.0 (reference) 
Yes 123 (88) 38 (60)  4.6 (2.0-10.5) 558 (83) 225 (58) 3.4 (2.5-4.6) 
       BMI (20 years b fore interview)      
       <22 56 (40)  12 (19) 1.0 (reference) 151 (22) 45 (12) 1.0 (reference) 
22.0-24.9 55 (39) 25 (40) 2.4 (0.9-6. ) 311 (46) 143 (37) 1.5 (1.0-2.3) 
25.0-29.9 22 (16) 16 (25) 4.3 (1. -13.1)) 196 (29) 164 (42) 2.7 (1.8-4. ) 
≥30.0 7 (5)  10 (16) 10.3 (2.6-42.3) 18 (3) 36 (9) 5.4 (2.6-10.8) 
       Cigarette smoking status (2 years b fore interview) 
       Never 90 (64)  29 (46)  1.0 (reference) 233 (35) 71 (18) 1.0 (reference) 
Previous 28 (20)  13 (21) 1.9 (0.7-5.1) 285 (4 ) 200 (5 )  2.3 (1.6-3.3) 
Current 22 (16) 21 (33) 5.3 (2.0-14.1) 158 (23) 117 (30) 2.8 (1.9-4.2) 
              
* Adjustments w re mad  for age, educational level, alcohol use, BMI, cigarette smoking, intake of fruit and 
vegetables, nd H. pylori infection.  
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Presence of gastroesophageal reflux symptoms increased the risk of esophageal and cardia 
adenocarcinoma over four times in female cases and three times in males (OR 4.6, 95% CI 2.0-
10.5 and OR 3.4, 95% CI 2.5-4.6). The risk seemed to rise with increasing severity of reflux 
symptoms in a dose-response manner, although women had an overall higher OR than men in 
all subcategories of exposure (data not shown).  
 
Being overweight twenty years before the interview was associated with an increased risk of 
esophageal or cardia adenocarcinoma with an OR of 4.3 (95%, CI 1.4-13-1) in women and a 
2.7 (95%, CI 1.8-4.1) in men. Obesity further increased the risk of cancer OR 10.3 (95%, CI 
2.6-42.3) in women and 5.4 (95%, CI 2.6-10.8) in men. The risk also seemed to rise with 
increased BMI in all subcategories (at age 20 years, minimum and maximum in life) (data not 
shown), and once again, female cases had higher point estimates than male in all BMI 
subcategories.  
 
Current tobacco smoking was associated with an increased risk of esophageal and cardia 
adenocarcinoma more than five times in women (OR 5.3, 95% CI 2.0-14.1) and almost three 
times in men (OR 2.8, 95% CI 1.9- 4.2). This risk factor also showed a seemingly dose-
response relationship, since higher frequency and duration of smoking was associated with 
increased risk (data not shown).  
 
To summarize, for all of the three studied risk factors, there was rather a possible increased risk 
of developing esophageal or cardia adenocarcinoma in women compared to men, implying that 
these risk factors do not explain the gender difference in incidence for these tumors.  
 
 
Preventive factors 
 
Both female and male cases were less exposed to the preventive factors of high intake of fruit 
and vegetables (45 compared to 37% in women and 32 compared to 25% in men) and infection 
with H. pylori, with the endotoxin CagA (19 compared to 16% in women and 24 compared to 
12% in men), when compared to female and male controls (Table 4). An increased risk of 
esophageal or cardia adenocarcinoma was observed in men with low intake of fruit and 
vegetables (OR 1.6, 95% CI 1.1-2.2) but not in women (OR 0.9, 95% CI 0.3-2.4), although this 
was not statistically significant. The protective effect of H. pylori-infection seen in men (OR 
0.5, 95% CI 0.3-0.8) was not found to be the same in women (OR 1.6, 95% CI 0.5-5.4).  
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Table 4. Preventive factors for esophageal and cardia adenocarcinoma in women versus men, expressed in OR with 
95% CI.  
 
Variables 
Women Men 
Controls Cases OR* Controls Cases OR* 
N = 140 (%)  N = 63 (%) (95% CI) N = 676 (%) N = 388 (%) (95% CI)  
       Intake of fruit and vegetables (20 years before interview)    
       Highest 63 (45) 23 (37) 1.0 (reference) 213 (32)  95 (25) 1.0 (reference) 
Medium 50 (36)  27 (43) 1.1 (0.5-2.5) 275 (41) 140 (36) 1.0 (0.7-1.4) 
Lowest 27 (19)  13 (21) 0.9 (0.3-2.4) 188 (28)  153 (39) 1.6 (1.1-2.2) 
       H. pylori status and its virulence factor CagA status     
       Negative HP and 
CagA 34 (24) 10 (16) 1.0 (reference) 161 (24) 90 (23) 1.0 (reference) 
Mixed HP or CagA 25 (18) 7 (11) 1.3 (0.4-4.7 92 (13) 68 (18) 1.2 (0.8-1.9) 
Positive HP and 
CagA 26 (19) 10 (16) 1.6 (0.5-5.4) 161 (24) 45 (12) 0.5 (0.3-0.8) 
Missing 55 (39) 36 (57) 2.8 (1.0-7.4) 262 (39) 185 (48) 1.1 (0.8-1.5) 
              
 
* Adjustments were made for age, educational level, alcohol use, BMI, cigarette smoking, intake of fruit and vegetables, 
and H. pylori infection.  
 
 
Stratified analysis for esophageal and cardia adenocarcinoma 
 
Additional analyses were conducted to determine point estimates for esophageal and cardia 
adenocarcinoma separately (Table 5). There were few female cases in some categories but the 
ORs for gastroesophageal reflux symptoms were particularly increased in esophageal 
adenocarcinoma for both women and men.  
 
 
Table 5. Risk for esophageal and cardia adenocarcinoma separately, presented as OR with 
95% CI.  
 
Variables 
Males Females 
Esophageal  Cardia Esophageal  Cardia 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
     Gastroesophageal reflux symptoms 
       No Reference Reference Reference Reference 
Yes 6.6 (4.4-9.9)* 2.0 (1.3-2.8)* 20.4 (4.4-94.2)* 1.4 (0.5-4.1)* 
          
 
*Adjustments were made for age, educational level, gastroesophageal reflux symptoms, BMI, 
tobacco smoking, intake of fruit and vegetables and HP.  
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Table 4. Preventive factors for esophageal nd c r ia denocarcinoma in women versus men, expressed in OR with 
95% CI.  
 
Variables 
Women Men 
Controls Cases OR* Controls Cases OR* 
N = 140 (%)  N = 63 (%) (95% CI) N = 676 (%) N = 388 (%) (95% CI)  
       Intake of fruit and vegetables (20 years before interview)    
       Highest 63 (45) 23 (37) 1.0 (reference) 213 (32)  95 (25) 1.0 (reference) 
Medium 50 (36)  27 (43) 1.1 (0.5-2.5) 275 (41) 140 (36) 1.0 (0.7-1.4) 
Lowest 27 (19)  13 (21) 0.9 (0.3-2.4) 188 (28)  153 (39) 1.6 (1.1-2.2) 
       H. pylori status and its virulence factor CagA status     
       Negativ  HP and 
CagA 34 (24) 10 (16) 1.0 (reference) 161 (24) 90 (23) 1.0 (reference) 
Mixed HP or CagA 25 (18) 7 (11) 1.3 (0.4-4.7 92 (13) 68 (18) 1.2 (0.8-1.9) 
Positive HP and 
CagA 26 (19) 10 (16) 1.6 (0.5-5.4) 161 (24) 45 (12) 0.5 (0.3-0.8) 
Missing 55 (39) 36 (57) 2.8 (1.0-7.4) 262 (39) 185 (48) 1.1 (0.8-1.5) 
              
 
* Adjustments were mad for age, educational level, alcohol use, BMI cigarette smoking, intake of fruit and vegetables, 
and H. pylori infect on.  
 
 
Stratified analysis for esophageal and c r ia a enocarcinoma 
 
Additional a yses were conducte  to e ermine point estimates for es phageal and car ia 
adenocarcinoma sep rately (Table 5). There w r  few female cas s in some categori s but the 
ORs for gastroesophageal r f ux sympto s were particularly increased in esophageal 
adenocarcinoma f r both w men and men.  
 
 
Table 5. Risk for es phageal and car ia a enocarcinoma sep rately, present d as OR with
95% CI.  
 
Variables 
Males Females 
Esophageal  Cardia Esophageal  Cardia 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
     Gastroesophageal reflux sympto s 
       No Referenc  Referenc  Referenc  Referenc  
Yes 6.6 (4.4-9.9)* 2.0 (1.3-2.8)* 20.4 (4.4-94.2)* 1.4 (0.5-4.1)* 
          
 
*Adjustments were mad  for age, educational level, gastroesophageal reflux sympto s, BMI, 
tobacc  smoking, intake of fruit and vegetables nd HP.  
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Paper II – Increased prevalence of reflux and obesity in the United Kingdom 
compared with Sweden: a potential explanation for the difference in incidence of 
esophageal adenocarcinoma 
 
 
In study II, an English population of 17,310 individuals in the age group 40-59 years was 
invited to participate, and 7,426 (43%) participants completed questionnaires and height and 
weight measurements. From these, 3,633 were randomly selected for analysis. In the Swedish 
population, 2,372 individuals in the age group 40-59 years were invited to participate, and 
1,483 (62%) participants completed the questionnaire.  
The Swedish participants were randomly selected to mimic sex and age distribution of 
esophageal adenocarcinoma patients, resulting in differences in the two populations regarding 
the distribution of age and gender (Figure 4).  
 
 
 
 
Figure 4: Distribution (ratios) of gender, age and education in the English and Swedish sample 
populations.  
 
 
The English population was younger, had a higher female percentage and less education than in 
the Swedish population, although these factors were adjusted for in the logistic regression 
analysis.  
 
 
Prevalence of risk factors for esophageal adenocarcinoma 
 
Occurrence of gastroesophageal reflux symptoms was more common in the English population; 
16.7% versus 8.8% (Table 6), and differences between the populations were further confirmed 
by an adjusted OR of 2.0 (95% CI 1.6-2.4) when using the Swedish population as a reference. 
The prevalence of a higher frequency and severity of gastroesophageal reflux was also more 
common in the English population, as shown by ORs of 2.2 (95% CI 1.6-3.0) for reflux 
symptoms once a week and 1.5 (95% CI 1.2-1.9) for a moderate problem of reflux symptoms 
(data not shown).  
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The prevalence of overweight and obesity was higher in the English population. More than 
65% of the participants from England had a BMI above 24.9 compared to 57% in the Swedish 
population. Mean BMI was also higher in the English population 28.3 (standard deviation ±0.3) 
versus 26.1 (standard deviation ±0.1) in the Swedish (data not shown). Also adjusted OR of 1.8 
(95% CI 1.5-2.1) for a BMI above 30 (obesity) was higher in the English population.  
The prevalence of tobacco smoking was similar in the two populations; the OR for prevalence 
of current smoking was 1.0 (95% CI 0.9-1.2) and the prevalence of former smoking was lower 
in the English population (OR 0.8, 95% CI 0.7-0.9).  
 
 
Table 6. Prevalence of risk factors for esophageal adenocarcinoma in samples of the English and Swedish 
population.  
 
Variable 
English 
sample 
Swedish 
sample 
OR*       
(95% CI) p value 
Number (%) Number (%) 
  
 
  
  Gastroesophageal reflux symptoms 
         No 2,835 (78.0) 1,290 (87.0) Reference  
Yes 607 (16.7) 130 (8.8) 2.0 (1.6-2.4) 0.000 
     BMI     
     <18.5 15 (0.4) 13 (0.9) 0.6 (0.3-1.3) 0.184 
18.5-24.9 1,237 (34.1) 631 (42.6) Reference  
25-30 1,565 (43.1) 595 (40.1) 1.5 (1.3-1.8) 0.000 
>30 816 (22.5) 244 (16.5) 1.8 (1.5-2.1) 0.000 
     Tobacco smoking status     
     Never 1,879 (51.7) 722 (48.7) Reference  
Current smoker 787 (21.7) 260 (17.5) 1.0 (0.9-1.2) 0.762 
Former smoker 921 (25.4) 466 (31.4) 0.8 (0.7-0.9) 0.001 
          
     
Gastroesophageal reflux symptoms, 
overweight/obesity and tobacco smoking 254 (7.0) 51 (3.4) 2.6 (1.9-3.7)** 0.000 
Gastroesophageal reflux symptoms and 
overweight/obesity 210 (5.8) 39 (2.6) 3.1 (2.1-4.6)** 0.000 
Overweight/obesity and tobacco smoking 839 (23.1) 362 (24.4) 1.4 (1.1-1.7)** 0.010 
Gastroesophageal reflux symptoms and 
tobacco smoking 62 (1.7) 23 (1.6) 1.4 (0.8-2.4)** 0.198 
        
 
* Adjusted for gender, age, education, BMI, and smoking status. Evaluated variable was excluded from the 
multivariable model.  
** Adjusted for gender, age and education.  
Percentages not adding to 100% are due to missing data.  
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Combined effects of risk factors 
 
Participants with a combination of gastroesophageal reflux, BMI ≥ 25 and tobacco smoking 
were almost three times (OR 2.6, 95% CI 1.9-3.7) more common in the English population and 
participants with a combination of the two major risk factors for esophageal adenocarcinoma 
(gastroesophageal reflux symptoms and a BMI ≥ 25) were more than three times (OR 3.1, 95% 
CI 2.1-4-6) as common in the English sample compared to the Swedish (Table 6).  
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Paper III – Risk factors for esophageal adenocarcinoma after antireflux surgery 
 
 
Of the 14,102 patients included in the antireflux cohort, 64 (0.45%) developed esophageal or 
cardia adenocarcinoma and 320 matched controls were randomly selected. Of these 384 
patients, 35 (8 cases and 27 controls) were excluded due to having had antireflux surgery for an 
indication other than GERD. Furthermore, 10 (1 case and 9 controls) participants were lost to 
follow-up as a result of a private hospital destroying medical records 10 years after the 
treatment session, resulting in a total of 55 cases and 240 controls included in this study. As a 
result of matching, cases and controls were similar in distribution of sex and age of antireflux 
surgery (data not shown).  
 
 
Risk of esophageal adenocarcinoma 
 
Recurrent reflux was 3 times more common in cases compared to controls (adjusted OR 3.1, 
95% CI 1.5-6.3, Table 7).  
 
 
Table 7. Risk of esophageal or cardia adenocarcinoma after antireflux surgery, expressed as OR with 
95% CI. 
 
Variable 
Cases  Controls   
 Adjusted model* 
   
Number (%)  Number (%)   
 OR 95% CI 
   
        
Recurrent reflux        
No  33 (60.0)  190 (79.2)    Reference 
Yes 19 (34.6)  43 (17.9)    3.1 (1.5-6.3) 
        
BMI        
< 25 13 (23.6)  69 (28.8)    Reference 
≥ 25 34 (61.8)  122 (50.8)    1.6 (0.8-3.5) 
        
Tobacco smoking        
Never 23 (41.8)  125 (52.1)    Reference 
Previous/current  26 (47.3)  102 (42.5)    1.4 (0.7-2.8) 
        
Type of antireflux surgery        
Partial fundoplication 17 (30.9)  53 (22.1)    Reference 
360 degree fundoplication 30 (54.6)  130 (54.2)    0.6 (0.3-1.3) 
Other 6 (10.9)  52 (21.7)    0.2 (0.1-0.7) 
         
 
*Matching was made for age, gender, and calendar year of antireflux surgery, and adjustments were made 
for age, gender, BMI, tobacco smoking, recurrent reflux and type of antireflux surgery.  
Percentages not adding up to 100% are due to missing data.  
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High BMI (>25) and ever smoking tobacco also seemed to increase the risk of esophageal or 
cardia adenocarcinoma (OR 1.6, 95% CI 0.8-3.5 and OR 1.4, 95% CI 0.7-2.8, respectively), 
although the results were statistically non-significant. A lower risk of cancer was suggested 
after Nissen (360 degrees) fundoplication compared to Toupét (partial) fundoplication, yet there 
was no statistically significant difference (OR 0.6, 95% CI 0.3-1.3). 
 
 
Cancer developed at least 5 years after surgery 
 
Analyses restricted to cases developing esophageal or cardia adenocarcinoma at least 5 years 
after the antireflux surgery revealed similar results as those of the entire sample (Table 8).  
 
 
Table 8. Risk of esophageal adenocarcinoma at least five years after antireflux surgery, expressed as 
OR with 95% CI. 
 
Variable 
Cases Controls Adjusted model* 
Number (%) Number (%) OR 95% CI 
    Recurrent reflux    
    No  19 (57.6) 112 (77.8) Reference 
Yes 12 (36.4) 28 (19.4) 2.9 (1.2-7.3) 
    BMI    
    < 25 5 (15.2) 37 (25.7) Reference 
≥ 25 21 (63.6) 76 (52.8) 2.4 (0.8-7.4) 
    Tobacco smoking    
    Never 15 (45.5) 76 (52.8) Reference 
Ever  12 (36.4) 61 (42.36) 0.9 (0.3-2.4) 
    Type of antireflux surgery    
    Partial fundoplication 9 (27.3) 33 (22.9) Reference 
360 degree fundoplication 17 (51.5) 78 (54.2) 0.7 (0.3-2.1) 
Other 5 (15.2) 30 (20.8) 0.4 (0.1-1.5) 
        
 
*Matching was made for age, sex, and calendar year of antireflux surgery, and adjustments were made for 
sex, age, BMI, tobacco smoking, recurrent reflux and type of antireflux surgery.  
Percentages not adding up to 100% are due to missing data.  
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Paper IV – Infection with human papillomavirus (HPV) in relation to site of 
squamous cell carcinoma of the esophagus 
 
 
During 1999 and 2006, 348 new cases of esophageal squamous cell carcinoma were reported in 
the Stockholm County. Of these, 67 (19%) were excluded because of tumor misclassification 
(n=3, 1%), diagnosis based on autopsy results only (n=11, 3%), or failure to identify any 
endoscopic biopsy (n=53, 15%). Among the 281 (81%) eligible patients, 77 (27%) were 
classified as non-participants due to absence (n=26, 9%) or lack of tumor material (n=51,18%). 
In the end, 204 patients (73%) remained for inclusion in the study. Sex and age distributions 
were similar between the groups, although tumor location differed due to missing data (Table 
9).  
 
 
 
Table 9. Differences between included and excluded patients.  
 
Variable 
Eligible patients Excluded patients 
Participants Non-participants Misclassification of tumor 
Missing, not 
found 
Detected at 
autopsy 
Number (%) Number (%) Number (%) Number (%) Number (%) 
      Total 204 (59) 77 (22) 3 (1) 53 (15) 11 (3) 
      Gender  
           Men 127 (62) 44 (57) 3 (100) 38 (72) 9 (82) 
Women  77 (38) 33 (43) 0 (0) 15 (28) 2 (18) 
      Age at diagnosis (years) 
          < 60 37 (18) 16 (21) 2 (67) 3 (6) 2 (18) 
60-70 76 (37) 26 (34) 0 (0) 22 (42) 4 (36) 
> 70 91 (45) 35 (45) 1 (33) 28 (53) 5 (45) 
      Tumor location 
          Proximal  53 (26) 17 (22) 1 (33) 4 (8) 1 (9) 
Middle/distal  147 (72) 56 (73) 1 (33) 29 (55) 4 (36) 
Unspecified/missing  4 (2) 4 (5) 1 (33) 20 (38) 6 (55) 
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Paper IV – Infection with human papillomavirus (HPV) in relation t  si e of 
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Detected at 
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Number (%) Number (%) Number (%) Number (%) Number (%) 
      Total 204 (59) 77 (22) 3 (1) 53 (15) 11 (3) 
      Gender  
           Men 127 (62) 44 (57) 3 (100) 38 (72) 9 (82) 
Women  77 (38) 33 (43) 0 (0) 15 (28) 2 (18) 
      Age at diagnosis (years) 
          < 60 37 (18) 16 (21) 2 (67) 3 (6) 2 (18) 
60-70 76 (37) 26 (34) 0 (0) 22 (42) 4 (36) 
> 70 91 (45) 35 (45) 1 (33) 28 (53) 5 (45) 
      Tumor location 
          Proximal  53 (26) 17 (22) 1 (33) 4 (8) 1 (9) 
Middle/distal  147 (72) 56 (73) 1 (33) 29 (55) 4 (36) 
Unspecified/m ssing  4 (2) 4 (5) 1 (33) 20 (38) 6 (55) 
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HPV and p16INK4a  
 
Among the 204 included patients, 20 (10%) were positive for HPV DNA; 18 (90%) of these 
tumors harbored HR HPV types, 1 (5%) pHR and 1 (5%) LR types (Table 10).  
 
 
 
Table 10. Human papillomavirus (HPV) types present in 
esophageal squamous cell carcinoma.  
 
HPV type  Number (%)  
  High-risk 
   HPV 16 13 (65) 
HPV 33 1 (5) 
HPV 45 1 (5) 
HPV 51 2 (10) 
HPV 52* 1 (5) 
HPV 73 1 (5) 
HPV 82* 1 (5) 
  Putative high-risk 
   HPV 66 1 (5) 
  Low risk  
   HPV 42 1 (5) 
    
     *Double infection with HPV 16 
 
 
 
The proportion of HPV positive tumors was higher in men than women (11% versus 8%) and 
highest in younger subjects. The proportion of HPV positive tumors was reduced with 
decreasing tumor differentiation. The prevalence of p16 expression was 24% in HPV-positive 
tumors and 16% in HPV-negative tumors, although these results were not statistically 
significant. 
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Association between HPV and tumor site  
 
The majority of the HPV-positive tumors (55%) were located in the middle third of the 
esophagus and the HPV-negative tumors were more frequently found in the distal esophagus 
(42%), although no statistically significant differences were observed (data not shown).  
 
Patients with HPV positive tumors were no more likely to have an proximal tumor than one in a 
middle or distal location (adjusted OR 0.6, 95% CI 0.2-1.9, Table 11). When comparing the 
proximal or middle versus distal tumor site the OR was possibly increased (OR 2.1, 95% CI 
0.7-6.3), although results were not statistically significant.  
 
 
 
Table 11. Risk of different sites for esophageal squamous cell carcinoma when exposed to HPV, 
expressed as OR with 95% CI.  
 
Variable 
Proximal Middle/distal   Crude model  Adjusted model* 
 
 
Number (%) Number (%)  OR 95% CI*  OR 95% CI# 
    
       Total 53 (27) 147 (74) 
    
       HPV status 
      Negative 49 (92) 131 (89) 
 
Reference 
 
Reference 
Positive 4 (8) 16 (11) 
 
0.7 (0.2-2.1) 
 
0.6 (0.2-1.9) 
              
 
* Adjustments made for sex, age and tumor differentiation.  
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DISCUSSION      
 
 
Methodological considerations  
 
 
General 
 
Epidemiology consists of two main study types: experimental and observational. In clinical 
settings, experimental studies refer to clinical trials, ideally randomized, where observed study 
participants are assigned to one of several exposures according to the researchers’ 
predetermined conditions.281 Observational studies describe the natural occurrence of exposures 
and outcomes which might introduce systematic errors.  
There are several differences between the main study types. To summarize, large randomized 
experimental studies are considered to have the highest validity, due to randomization 
contributing to the decreased occurrence of systematic errors and are ranked highest in the 
hierarchy of studies in evidenced based medicine (EBM).282 However, some experts argue that 
the internal validity of individual studies should determine the hierarchy rather than the study 
design.283 Experimental studies interfere with the natural course of events and are not feasible 
or ethically possible for certain research hypotheses, especially not when investigating 
etiological factors and observational studies are required.  
This thesis investigated etiological factors for esophageal cancer using observational study 
design exclusively.  
 
 
Study design  
 
The studies included in this thesis are based on various epidemiological designs, some of which 
are relatively uncommon. Cohort-, case-control- and cross sectional studies are all examples of 
observational studies. A cohort study measures the frequency of a disease in exposed and 
unexposed participants; a case-control study assesses exposure measurements in participants 
with a specific disease and compares them to individuals without the disease, and a cross 
sectional study samples information on both the exposure and the disease at the same point in 
time.  
 
 
Cohort study  
 
Cohort studies have been described as “the archetype of all epidemiological studies”.284 They 
consist of a group of individuals with specific characteristics (exposed or unexposed) followed 
over time to measure the disease occurrence within the group at the end of follow-up. A cohort 
study usually consists of two groups (exposed and unexposed) and compares their disease rates.  
The main advantages of cohort studies include obtaining complete information on the study 
exposure, temporal measurement of the exposure and disease, reduced risk of selection bias and 
recall bias when using a prospective design, and the ability to study multiple outcomes. The 
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main drawbacks of cohort studies are their inefficiency and high costs, usually due to long 
induction time and large quantity of individuals followed.  
 
 
Case-control study  
 
In a case-control study, individuals with a specific disease (cases) are identified and compared 
to individuals from the same source population without the disease under study (controls). The 
control group aims to mirror the exposure characteristics occurring in the source population and 
controls should be chosen after careful consideration in order to reduce selection bias. The 
exposure is usually measured retrospectively which might introduce recall bias.  
Case-control studies are, in general, more efficient than prospective cohort studies. The use of 
sampling instead of following a cohort for several years is both cost- and time efficient, making 
the case-control study design suitable for esophageal cancer with its low incidence and long 
induction time. Disadvantages of the case-control design include the risk of selection bias when 
choosing controls, recall bias when collecting data of study exposure retrospectively and 
confounding.  
 
The case-control study design was used in papers I, III, and IV in this thesis. Paper I was a 
prospective population-based case-control study covering new cases of esophageal and cardia 
adenocarcinoma in the Swedish population. The exposures and outcome were measured 
retrospectively. Controls were randomly selected from the Swedish Register of the Total 
Population through frequency matching within a ten-year age and gender strata in order to 
mimic the distribution of the cases.  
Paper III was a population-based nested case-control study within a cohort of all antireflux 
operated patients in Sweden. Study exposures were obtained through examination of medical 
records from the primary antireflux surgery and up to two years after. Outcome was assessed 
through the linkage of personal identity numbers to the Swedish Cancer Register.  
Paper IV was a population-based case-control study conducted within the Stockholm County. 
Exposure was assessed through laboratory measures and outcome was assessed through the 
examination of medical records.  
 
 
Cross-sectional study 
 
In contrast with longitudinal studies, in which information is collected at more than one time 
point, cross-sectional studies sample information from the source population at only one point 
in time; a cross-sectional study examining prevalence is known as a prevalence study. The 
advantages of cross-sectional studies are that they are generally easy and inexpensive to 
implement. The disadvantages include the inability to establish temporal relations, i.e. difficulty 
in assessing time order of exposure and outcome resulting in an increased risk of reverse 
causality.  
 
A cross-sectional design was used in paper II, when population prevalence of known risk 
factors for esophageal adenocarcinoma was compared in the English and Swedish populations. 
The study only investigated differences in population prevalence of known risk factors.  
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Population-based  
 
A study representative of an entire population is said to be population-based. In order to define 
a case-control study as population-based, all cases, or a random sample (representative of all 
cases) of cases and their corresponding randomly selected controls from a predetermined 
population for a specific time period, have to be included. In reality, 100% completeness is 
rarely possible but a high participation rate is important. The greatest advantage with the 
population-based study design is the minimal risk of selection bias. Sweden has the advantage 
of virtually free public health care in combination with large and complete population registers. 
Cancer cases are typically managed in the public health care system and registered in the 
Swedish Cancer Register making this country highly suitable for population-based cancer 
research. Individuals are identified through their unique personal identity number, and 
information can be linked between several population registers.  
All studies included in this thesis were more or less population-based, depending on which 
level of non-participation rate is acceptable when using this definition. Nevertheless, papers I 
and III covered the entire Swedish population and paper IV included the entire population of 
the Stockholm County. Paper II covered two populations including the entire Swedish and 
defined parts of the English population.  
 
 
Validity  
 
The main objectives of epidemiological studies are to determine a valid and precise estimate of 
the studied hypothesis. There are two major sources of error that can be problematic in 
epidemiological studies: systematic error, the opposite of validity (commonly referred to as 
bias), and random error, the opposite of precision (further described below).  
Validity can be separated into two components: internal and external, where internal validity 
refers to the degree of systematic error within the study, i.e. to what extent the study measures 
what it aims to measure. The internal validity is of importance when evaluating study quality 
and high internal validity is necessary for external validity (generalizability). External validity 
(further described below) refers to what degree findings can be translated into other 
populations, i.e. the ability to apply results to populations outside the study. Internal validity is 
commonly classified into three groups: selection bias, information bias and confounding.  
 
 
Selection bias  
 
Selection bias is introduced if the exposure or the disease under study, influences the selection 
of study participants i.e. the exposure or disease patterns, differs between participants and non-
participants. A historically famous example of selection bias is the “healthy worker effect”, 
where workers included in a study are healthier than the average population, resulting in 
differences between study participants and non-participants regarding exposure (workers have a 
more healthy lifestyle) and disease (low incidence of disease). In this thesis, population-based 
study designs were used in all studies as an attempt to reduce selection bias, although it cannot 
be ruled out.  
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Paper I was based on the SECC-study, which had a high participation rate (85%) among the 
cases, which indicates a limited risk of selection bias. The participation was, however, lower in 
control subjects (72%), which introduces a higher risk of selection bias. In order to evaluate 
whether these subjects were different from the participants, separate analyses were performed 
on 24 control subjects who initially refused to participate but then changed their mind after 
some persuasion. Analyses showed no differences between participants and the 24 control 
subjects regarding background data or risk factor exposure, indicating that non-participating 
controls were not obviously different from those who participated.  
 
Paper II was based on a questionnaire filled out by a random sample of the English and 
Swedish populations. The recruitment of participants was different in the English and Swedish 
populations with regards to sampling and inclusion which might have consequently introduced 
selection bias. Selection bias might also have been introduced from non-responders, especially 
in the English population, where the participation rate was limited (43%). Unfortunately, no 
analyses were available to investigate differences between participants and non-participants in 
this study, and selection bias cannot be ruled out.  
 
In paper III, cases and controls were selected from the same cohort with a good rate of 
participation (86% and 75%). Therefore, the risk of selection bias should be low.  
 
Paper IV had a large proportion of non-participation which was mainly due to lack of tumor 
material. Non-participants always potentially introduce selection bias although, when 
comparing participants to non-participants (Table 8), the groups were equally distributed 
regarding sex, age and the available tumor location indicating that selection bias might not have 
been a substantial error in this study.  
 
 
Information bias 
 
Information bias, also known as misclassification, is introduced when information about study 
subjects is incorrectly assimilated. Misclassification of exposures or outcomes can be non-
differential or differential depending on whether the level of misclassification differs between 
cases and controls. Non-differential misclassification, to some extent present in almost all 
studies, is unrelated to the outcome although it dilutes the estimate, i.e. moves the estimate 
closer towards the null value. Differential misclassification implies that misclassification differs 
between cases and controls which can then distort the estimate in either direction. Recall bias is 
a form of misclassification of particular concern in case-control studies when exposure is 
collected retrospectively, i.e. after the outcome or disease has occurred. Cases, affected by the 
disease, tend to recall exposure differently compared with controls, thus introducing differential 
misclassification.  
 
Paper I has several potential risks of differential misclassification of the exposure. Non-blinded 
professional interviewers conducted the interviews, however, they were unaware of the study 
hypothesis and specially trained to treat cases and controls no differently. Recall bias regarding 
exposure of gastroesophageal reflux symptoms, which occurs in the same organ as the cancer, 
is also possible. However, recall bias does not seem to be of importance since information on 
both adenocarcinoma and squamous cell carcinoma was collected without similar results of 
exposure. Reverse causality, i.e. the outcome (esophageal tumor) causing (gastroesophageal 
reflux) symptoms which are interpreted as exposure, was also considered and avoided by all 
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questions focusing on a time period at least 5 years prior to diagnosis. Misclassification of 
disease is rather unlikely, as sizable efforts were made to ascertain the exact tumor location and 
type and tumor material was thoroughly re-examined by an experienced pathologist.  
 
Self-reported questionnaires used in paper II could have introduced non-differential 
misclassification of the exposure, although this ought to be of limited importance. The 
collection of BMI data, which was measured in the English population and self-reported in the 
Swedish, is a greater cause for concern. Although there are reports implying that anonymous 
self-reported height and weight are fairly accurate,276 it is likely that differential 
misclassification of exposure may have been introduced and results including BMI should be 
interpreted with caution. Another concern is that data was collected during different time 
periods, in the late 1990s in the English population and in 2008 in the Swedish population. The 
prevalence of the evaluated risk factors might have increased during this time,120 285 making it 
possible that the true magnitude of difference between the two populations is rather greater than 
that observed.  
 
Paper III was partly based on data collected from medical records, which might have introduced 
differential misclassification. The examiner was, however, blinded to case-control status and 
records were created long before the outcome of the disease which should reduce any such 
error. Moreover, only medical records from the point of a primary antireflux operation and up 
to two years after surgery were collected, in order to avoid obtaining information about 
esophageal cancer. This would make the misclassification of exposure similar in both cases and 
controls (non-differential). Separate analyses were also performed for cases that developed 
esophageal or cardia adenocarcinoma at least 5 years after surgery so as to exclude the risk of 
earlier detection of currently undiagnosed cancer, i.e. detection bias. An advantage of paper III 
was that both cases and controls shared the pre-operative risk factor profile, including 
gastroesophageal reflux, since antireflux surgery is typically performed only in patients with 
severe reflux. Disease misclassification is unlikely in this study since cases were identified 
through the valid and complete Swedish Cancer Register.  
 
In paper IV, misclassification of the HPV-exposure might have been introduced due to high 
sensitivity in laboratory analyses, i.e. HPV DNA irrelevant for tumor development might have 
been identified, although this misclassification is likely to be non-differential since all 
examiners were blinded to case-control status. Furthermore, measurement of the outcome might 
have introduced misclassification, both when clinicians reported tumor location (individualized) 
and when the investigator examined medical records for tumor location, although any such bias 
should be limited since a single pathologist re-examined all biopsy specimens.  
 
 
Confounding  
 
Confounding can be described as the mixing of the effects of a measured exposure and other 
known or unknown variables.284 Confounding is of great interest in all epidemiologic study 
designs, especially in observational studies where randomly assigned exposure is impossible. A 
confounder must be associated with both the exposure and the disease and not be an effect of 
the exposure (intermediator) on the outcome.  
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The relation between gastroesophageal reflux symptoms, obesity and the development of 
esophageal or cardia adenocarcinoma might illustrate an example of a possible confounder 
present in papers I-III. Gastroesophageal reflux symptoms (exposure) are causally linked with 
esophageal and cardia adenocarcinoma5 and obesity is associated with both gastroesophageal 
reflux symptoms (increasing the exposure) and these tumors (a risk factor for the outcome) 
making it a potential confounder. Confounding can be reduced or controlled through the design, 
e.g. by matching or other planned selection of cases and controls, stratification and use of 
multiple regression analysis. The use of matching is difficult, since it might introduce bias if 
selection is based on factors correlated to the study exposure.281 Matching was used in paper I, 
and multivariable regression analysis was conducted in all studies.  
In paper IV, there was little information about potential confounders, including strong risk 
factors such as tobacco smoking and alcohol. However, since all included participants had the 
same disease, the causal exposures other than infection with HPV are unlikely to differ between 
cases and controls.  
To summarize, even though confounding have been carefully considered in this thesis, residual 
confounding from the studied variables or from other known or unknown variables can never 
be fully excluded.  
 
 
Generalizability  
 
Generalizability is, as mentioned previously, the external validity of conclusions in a study, i.e. 
the ability to apply results to populations outside the study. The external validity is dependent 
on the internal validity, i.e. how well the study population reflects characteristics of the entire 
population, which is of greater importance when measuring accuracy in a study. The internal 
validity needs to be proven before the results can be considered and applied to other 
populations. Each study needs to be evaluated separately regarding generalizability. 
 
 
Precision 
 
The precision of a study is determined by the amount of random error or chance, i.e. if the study 
contains a sizeable random error, the precision will be poor. As opposed to systematic error, 
where the study design is used to reduce error, random error is decreased by increasing the size 
of the study population.  
Precision, or the amount of random error in a study, can be tested in statistical analyses and 
presented as a CI or p-value. The CI is calculated from the point estimate and the selected level 
of significance. If set to 95%, then 95% of the point estimates from all new randomly drawn 
samples from the same source population will be included in the CI. The p-value is calculated 
in relation to the null hypothesis and is derived from the same equation as the confidence 
interval. It is defined as a “measure of the compatibility between the hypothesis and the 
data”.281 If the data is in accordance with the null hypothesis the p-value is non-significant, i.e. 
above 0.05. There are two types of chance errors in hypothesis testing, type I and type II.  
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Type I errors occur when the null hypothesis is rejected even though it is true, which means that 
the association between the exposure and outcome is statistically significant, even though no 
true association exists. The probability of making a type I error is dependent on the level of 
significance used, generally α=0.05. Type I errors are a threat to all studies, particularly those in 
which several analyses are performed, as multiple testing would result in type I errors in 5% of 
the tests if α=0.05. In this thesis, attempts were made to avoid or reduce risk of type I error by 
writing and following study protocols where hypotheses, categorization of variables and choice 
of statistical analyses were pre-determined.  
 
Type II errors occur when the null hypothesis is not rejected when it is false, meaning that there 
is an association between the exposure and outcome, although it is not detected. Type II errors 
may arise when using an inappropriate study design, when collection of exposure and outcome 
data is poor, or when the statistical power is low. Power is defined as the ability of the test to 
correctly reject the null hypothesis and is dependent on sample size, level of significance and 
the size of the effect measured. It is usually set to 80%, meaning that every fifth test will not 
detect a true association. The statistical power was limited in evaluating cancer risk in papers I, 
III and IV due to the low incidence of esophageal and cardia cancer.  
 
Finally, there is an ongoing discussion in the research community regarding quality of studies 
being determined by statistical significance (p-value < 0.05) rather than biological background 
and validity.281 Therefore, it is important to point out that both CI and p-values assume that 
there are no systematic errors and that the statistical significance is of limited importance when 
implicating results from a study.  
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Findings and implications  
 
 
Difference in risk factor profiles in women and men 
 
Contradictory to the study hypothesis, paper I found no decreased strengths in the risk factors of 
esophageal or cardia adenocarcinoma (gastroesophageal reflux symptoms, obesity and tobacco 
smoking) in women compared to men. Furthermore, the protective factors (high intake of fruit 
and vegetables, infection with H. pylori) occurring in men were absent in women.  
 
Paper I showed the important role of gastroesophageal reflux symptoms and obesity in the 
etiology of esophageal and cardia adenocarcinoma in both genders. Exposure to tobacco 
smoking only moderately increased the risk of cancer, whereas the protective role of high 
intake of fruit and vegetables and H. pylori infection was seen only in men. Paper I was in 
agreement with another large population-based case-control study examining risk factors for 
esophageal cancer in relation to gender.7 The association between obesity and cancer 
development was similar in women and men (OR 1.9, 95% CI 0.9-4.1 compared to 1.7, 95% CI 
1.2-2.5) although the results in women were statistically non significant. Statistical power was a 
main problem in paper I, resulting in limited precision. The problem arose as esophageal and 
cardia adenocarcinomas are rare diseases, especially in women. If the statistical power in paper 
I had been stronger, we might have been able to confirm that known risk factors are in fact 
stronger in women. However, the results indicate that the association between known risk 
factors and the risk of esophageal and cardia adenocarcinoma are similar in both genders, which 
cannot explain the male predominance in these types of cancer.  
 
Paper I showed no difference in risk factor profiles between women and men, which is contrary 
to our study hypothesis and to what would be expected since men have a much higher incidence 
rate of esophageal and cardia adenocarcinoma (1:3-7).11 20 44 84 90 A possible explanation is that 
women are exclusively protected from developing these cancers by some other yet unidentified 
factor. The role of estrogen as a protective factor has been suggested and evaluated without any 
clear results. Some studies indicate that a history of breast-feeding is associated with a 
decreased risk of esophageal and cardia adenocarcinoma286 287 although other studies of 
estrogen show no protective effect or inconclusive results.95 96 288 Furthermore, higher 
production and concentration of gastric acid,91 higher prevalence of hiatus hernia, abnormal 24-
h pH test and defective LES in patients with symptomatic gastroesophageal reflux92 and 
abdominal/android obesity93 resulting in higher intra-abdominal and intra-gastric pressure are 
all more common in men and have been suggested to explain the male predominance. However, 
more research is needed before the role of each of these factors can be established as an 
explanation for the male predominance.  
 
In conclusion, paper I did not find an explanation for the male predominance in esophageal and 
cardia adenocarcinoma; established risk factors are similarly strong in both women and men.  
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Difference in population prevalence of risk factors for esophageal adenocarcinoma 
 
Paper II suggests that the prevalence of the established risk factors for esophageal 
adenocarcinoma, i.e. gastroesophageal reflux symptoms and obesity, are higher in the English 
population compared to the Swedish which might contribute to the explanation of the 
significantly higher incidence of esophageal adenocarcinoma in England.  
 
The incidence of esophageal adenocarcinoma is approximately five times higher in England 
than in Sweden.45 Results from paper II are in line with the hypothesis that this difference is due 
to the higher prevalence of established risk factors for esophageal adenocarcinoma in the 
English population. Some previous research also shows that the prevalence of gastroesophageal 
reflux symptoms117 and obesity155 is higher in the English population. The frequency of tobacco 
smoking was found to be similar in the populations but it is considered as a weaker risk factor.43 
172 Compared with previous studies, paper II is the first to use population-based sampling with 
an identical questionnaire in both populations. Although BMI was measured differently and 
data collection was performed at two different point in time, it might not explain the differences 
between the populations, since anonymous self-reported values of current weight have been 
validated and found to be accurate measurements of the true value276 and the prevalence of risk 
factors have rather increased in the English population since data was collected.120 285 
Furthermore, difference in sex and age distribution between the two samples would not explain 
the results since these factors were adjusted for in the logistic regression analysis.  
 
Esophageal cancer is a form of cancer associated with late diagnosis12 and poor prognosis13 and 
the incidence of esophageal adenocarcinoma has increased very rapidly during the last three 
decades3 4 11 83-85 making preventive measures highly desirable and important. Paper II provides 
evidence indicating that the higher incidence of this type of cancer is due to the higher 
population prevalence of gastroesophageal reflux symptoms and obesity. This raises the 
question that if we can reduce these factors, will it also reduce the incidence of this cancer 
form? As yet neither medical nor surgical treatment against gastroesophageal reflux has been 
shown to have a cancer protective effect (further discussed below in paper III)27 34 145-149 152 and 
regarding obesity, paper II adds yet another reason for aiming to keep BMI within a normal 
range.  
 
In conclusion, the prevalence of the exposures reflux and obesity are at least several times more 
common in the English population thus supporting our hypothesis that the higher incidence of 
esophageal adenocarcinoma in the English population can be due to the higher presence of 
these risk factors.   
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Risk of cancer after antireflux surgery 
 
Paper III provides some evidence that recurrent reflux is more common in antireflux operated 
patients who subsequently develop esophageal or cardia adenocarcinoma compared to those 
who do not develop this cancer form. However, other established risk factors for this cancer, i.e. 
obesity and tobacco smoking and type of antireflux surgery do not seem to have any influence 
on development of esophageal or cardia adenocarcinoma.  
 
The antireflux cohort used in this study has previously revealed no cancer protective effect from 
antireflux surgery145 and 0.45% (64/14,102) of patients, which is equivalent to the proportion of 
patients with BE (0.1-0.6%),37-40 did go on to develop cancer. The purpose of paper III was to 
investigate risk factors that can identify patients that will or will not develop esophageal or 
cardia adenocarcinoma after antireflux surgery. The results indicate that recurrence of reflux is 
a key exposure and results are in line with some animal studies, suggesting that subtotal reflux 
control with continued acid pulses is likely to increase proliferation and decrease differentiation 
in Barrett’s epithelium.289 290 Furthermore, some clinical studies suggest that recurrent reflux 
after surgery might explain the failed protective effect of antireflux surgery.149 150 It is also 
known that antireflux surgery is not guaranteed to control GERD. A substantial number of 
patients suffer from recurrent GERD and need antireflux medication after such surgery.291 
Other risk factors such as overweight and tobacco smoking seem to be of less importance after 
antireflux surgery although paper III has limited statistical power. A surgical technique of 
“other” choice (mostly plication of crural crus or vagotomy, no fundoplication) seems to 
decrease the risk of cancer, which is not too surprising since the removal of the vagal nerve will 
decrease the level of gastric acid secreted, i.e. reducing the gastroesophageal reflux. However, 
the operation has many side effects making it unsuitable for most patients.  
 
With regards to prevention, gastroesophageal reflux is the strongest risk factor for esophageal 
adenocarcinoma,5 no cancer protective effect has been observed from either medical or surgical 
treatment of this condition and, as a result, antireflux surgery is no longer recommended as 
cancer protective treatment and should not be performed with this purpose in mind.27 34 145-149 152 
Our study provides results that might explain the lack of cancer protective effect after surgery 
and suggests that separate analyses might be relevant for patients with and without recurrent 
reflux when examining the cancer preventive results of surgery.  
 
In conclusion, paper III indicates that recurrence of reflux is a strong risk factor for the 
development of esophageal adenocarcinoma after antireflux surgery. This finding could at least 
partly explain the lack of cancer preventive effect of antireflux surgery. Endoscopic 
surveillance might be considered in patients who develop recurrent GERD after antireflux 
surgery.  
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HPV infection and tumor location 
 
Paper IV does not provide any support for an increased rate of HPV infection in patients with a 
proximal location of squamous cell carcinoma in the esophagus compared with a more distal 
site. The study also indicates a limited presence of HPV in esophageal squamous cell carcinoma 
in a Swedish population and does not support a carcinogenetic role of HPV in tumors based on 
p16INK4a data.  
 
Infection with HPV is the strongest risk factor for cervical cancer1 and has recently also been 
accepted as a causal factor for oropharyngeal cancer.242 243 The relation between esophageal 
squamous cell carcinoma and HPV infection is unclear and results vary from total absence to 
more than 70% of tumors being positive for HPV.258-267 This situation is reminiscence of the 
results in head-neck squamous cell carcinoma before researchers realized that HPV was 
connected to oropharyngeal cancers and not all tumors in the oral cavity. For this reason, and 
because of the suspected oral route of viral transmission, we hypothesized that tumor location is 
associated with presence of HPV infection. However, results from paper IV did not support this 
hypothesis. In addition, the presence of HPV in general was low (10%), and since no 
correlation with p16 was found, it is questionable as to whether the presence of the virus 
actually causes esophageal squamous cell carcinoma. Compared to other European studies, 
paper IV found a slightly lower prevalence of HPV DNA in squamous cell tumors.265-267 
Possible explanations might be geographic differences or use of a smaller DNA sample, 
although this might be of limited relevance since a highly sensitive laboratory method was 
used.234 Other concerns include selection bias introduced by patients excluded from certain 
hospitals and known risk factors (tobacco smoking and alcohol abuse) not being directly 
measured. However, the design comparing patients with esophageal squamous cell carcinoma 
counteracts confounding by these risk factors. Another methodological advantage was the use 
of endoscopic biopsies in all participants since it avoided introduction of bias when detecting 
HPV in different tumor sites.  
 
The highest prevalence of HPV DNA was found in the middle part of the esophagus. This 
might merely be an effect of chance or speculatively this might be a true finding. The middle 
part of the esophagus, the transition zone (between striated muscles in the proximal part and 
smooth in the distal part of the esophagus) holds no significant contraction amplitude when 
measuring peristaltic contractions292 and this region, together with the proximal part of the 
esophagus, is collapsed during resting state which might allow virus particles to implant more 
easily, although this is highly speculative.  
To our knowledge, this is the first study comparing the association between HPV infection and 
the development of esophageal squamous cell carcinoma in different locations as the primary 
endpoint.  
 
In conclusion, paper IV revealed no support for the hypothesis that HPV infection would be 
more likely to cause proximal than distal esophageal tumors.   
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CONCLUSION      
 
 
¥ Differences in risk factor profiles of known risk factors between women and men do 
not seem to explain the male predominance in esophageal and cardia 
adenocarcinoma.  
 
¥ Prevalence of the risk factors gastroesophageal reflux symptoms and being 
overweight seem to be more common in the English population compared to the 
Swedish and this may in turn contribute to the higher incidence of esophageal 
adenocarcinoma in England.  
 
¥ Recurrence of reflux after antireflux surgery is a risk factor for subsequent 
development of esophageal adenocarcinoma and might explain the lack of a cancer 
preventive effect of antireflux surgery. Endoscopic surveillance may be considered in 
patients who develop recurrent GERD after antireflux surgery 
 
¥ There is no apparent increased occurrence of HPV DNA in esophageal squamous cell 
carcinomas located in the proximal compared to the more distal parts of the 
esophagus.  
 
 
 
 
 
  
S 
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FUTURE STUDIES     
 
 
The results from this thesis give rise to some additional questions that need to be resolved in 
future studies.  
 
The male predominance in esophageal adenocarcinoma remains a mystery. Paper I suggested 
that differences in risk factor profile cannot explain the prevailing gender difference. Further 
studies are needed, including investigations of the role of sex hormones.  
 
Due to the poor prognosis associated with esophageal cancer, there is an urgent need for 
preventive measures. Paper II suggests that a higher population prevalence of known risk 
factors increases the incidence of esophageal adenocarcinoma. Preventive measures against 
GERD and obesity would appear to be required. Paper III, however, suggests that antireflux 
surgery might not be a good cancer preventive option for patients with severe GERD although 
further studies are needed in order to be sure of these results.  
 
Paper IV dismissed HPV as a risk factor associated with a proximal location of esophageal 
squamous cell carcinoma although more studies are needed. Future research needs to determine 
a universal laboratory technique for detection of HPV to make comparison of results between 
studies possible.  
 
 
 
 
 
  
  64 
POPULÄRVETENSKAPLIG SAMMANFATTNING  
 
 
Bakgrund 
 
Matstrupscancer är den åttonde vanligaste cancerformen och den sjätte vanligaste dödsorsaken 
till följd av cancer i världen. Det finns två huvudtyper av matstrupscancer, skivepitelcancer (en 
malign tumör som uppstår i matstrupens normala ytskikt) och adenocarcinom (en malign tumör 
som uppstår när matstrupens normala ytskikt ersatts av ett körtelformat ytskickt). 
Skivepitelcancer dominerar globalt, men under de senaste decennierna har förekomsten av 
adenocarcinom ökat snabbt och utgör numera ungefär hälften av alla matstrupscancrar i 
västvärlden. Riskfaktorer för skivepitelcancer är främst rökning och högt alkoholintag, medan 
högt intag av frukt och grönsaker har skyddande effekt. För adenocarcinom är gastroesofagal 
refluxsjukdom (reflux) den dominerande riskfaktorn tillsammans med fetma och manligt kön, 
medan rökning enbart medför en något ökad risk. Högt intag av frukt och grönsaker samt 
infektion med bakterien Helicobacter pylori (H. pylori) har visat sig ha skyddande effekt.  
På grund av matstrupens höga elasticitet ger tumörer i detta organ som regel inte symtom förrän 
sent i förloppet, vilket bidrar till matstrupscancerns ytterst dåliga prognos. Minst hälften av alla 
patienter har en inoperabel tumörsjukdom eller metastaser (”dottertumörer”) vid 
diagnostillfället. Trots försök att utveckla och förbättra behandlingen är det fortfarande bara 
cirka 10% av patienterna i Europa som överlever mer än 5 år. Förebyggande åtgärder är därför 
av yttersta vikt. 
 
I avhandlingen ingår följande delarbeten:  
 
Arbete I: Könsspecifik riskfaktorprofil vid adenocarcinom i matstrupen.  
Arbete II: Kan ökad förekomst av reflux och fetma i England jämfört med Sverige förklara 
varför England har en mycket högre förekomst av adenocarcinom i matstrupen?  
Arbete III: Riskfaktorer för adenocarcinom i matstrupen efter antirefluxoperation.  
Arbete IV: Infektion med humant papillomavirus i relation till tumörlokalisation av 
skivepitelcancer i matstrupen.  
 
Arbete I: Matstrupscancer drabbar huvudsakligen män. Förekomsten av skivepitelcancer är 
dock lika mellan könen när skillnader i rök- och alkoholvanor korrigerats för. Det finns däremot 
ingen förklaring till att adenocarcinom är betydligt vanligare bland män, med en könsfördelning 
på hela 7:1. Vår hypotes var att mansdominansen i adenocarcinom till viss del kan förklaras av 
att riskfaktorprofilen skiljer sig mellan kvinnor och män.  
Arbete I testade hypotesen genom att studera alla kvinnliga och manliga fall av adenocarcinom 
i Sverige mellan 1 december 1994 och 31 december 1997. Cancerfallen jämfördes med 
slumpmässigt utvalda kontrollpersoner ur den svenska befolkningen. Samtliga deltagare 
intervjuades av professionella intervjuare från Statistiska Centralbyrån angående riskfaktorer 
för adenocarcinom i matstrupen (reflux, fetma, rökning, samt intag av frukt och grönsaker). 
Blodprov samlades även in för att se om deltagarna var infekterade med bakterien H. pylori.  
Resultaten var i stort sett raka motsatsen till vår hypotes. Riskfaktorerna reflux, fetma och 
rökning var lika starkt associerade med matstrupscancer hos både kvinnor och män, samtidigt 
som de skyddande faktorerna (högt intag av frukt- och grönsaker, samt infektion orsakad av H. 
Pylori) visade liten eller ingen skyddande effekt hos kvinnor. Eftersom sambandet mellan 
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etablerade riskfaktorer och adenocarcinom i matstrupen var lika för båda könen, talar resultaten 
för att kvinnor har någon typ av okänd skyddsmekanism som motverkar utveckling av denna 
typ av cancer.  
 
Arbete II: Det finns stora och oförklarade skillnader i förekomst (incidens) av adenocarcinom i 
matstrupen mellan olika västerländska populationer. Storbritannien har den högsta incidensen i 
världen, cirka 5 gånger högre än i Sverige. Kunskap om orsakerna till denna skillnad skulle 
kunna förklara vilka faktorer som ligger bakom de senaste decenniernas snabba incidensökning 
i västvärlden, och därmed öppna nya dörrar för förebyggande åtgärder.  
Arbete II jämförde förekomsten av de väletablerade riskfaktorerna för adenocarcinom i 
matstrupen (reflux, fetma och rökning) mellan den engelska och svenska befolkningen. Ett 
slumpmässigt urval av befolkningarna i England och Sverige i åldrarna 40-59 år, besvarade en 
enkät innehållandes detaljerade frågor om dessa riskfaktorer.  
Resultaten visade att förekomsten av reflux och fetma var betydligt högre i den engelska 
befolkningen jämför med den svenska, något som skulle kunna förklara den högre incidensen 
av adenocarcinom i England.  
 
Arbete III: Reflux, den dominerande riskfaktorn för adenocarcinom i matstrupen, är en 
folksjukdom som drabbar cirka 10-20% av den vuxna västerländska befolkningen. Reflux 
behandlas oftast medicinskt, men kan även i svåra fall behandlas med kirurgi, vilket mekaniskt 
motverkar att magsyra når matstrupen. Något överraskande finns i dagsläget inga belägg för att 
varken medicinsk eller kirurgisk refluxbehandling leder till minskad risk för utveckling av 
adenocarcinom i matstrupen. Tänkbara orsaker till att kirurgisk behandling inte har en 
förebyggande verkan är att operationen inte är tillräckligt effektiv eller att andra riskfaktorer för 
adenocarcinom (fetma och rökning) spelar in och är vanligare bland de patienter som utvecklar 
cancer efter operation.  
Arbete III undersökte faktorer som kan skilja patienter som utvecklar adenocarcinom i 
matstrupen efter antirefluxkirurgi från dem som inte gör det. I studien identifierades samtliga 
patienter som behandlats med antirefluxkirurgi och utvecklat adenocarcinom mellan 1965 och 
2006. För varje fall valdes 4-5 kontrollpersoner slumpmässigt från de patienter som behandlats 
med antirefluxkirurgi samtidigt som fallen, men inte utvecklat cancer. Journaler granskades för 
både fall och kontroller, med avseende på återkomst av reflux efter operationen, samt fetma och 
rökning.  
Resultaten visade att de patienter som utvecklade matstrupscancer hade betydligt större 
benägenhet för återkommande reflux efter operationen, något som skulle kunna förklara varför 
man inte observerat någon skyddande effekt av antirefluxkirurgi. Arbete III indikerar att 
patienter med återkommande reflux efter antirefluxkirurgi bör övervakas regelbundet och att 
framtida studier som undersöker den potentiellt preventiva effekten av antirefluxkirurgi bör 
separera patienter som har och inte har fullgott refluxskydd efter operationen.  
 
Arbete IV: Infektion med humant papillomavirus (HPV), kanske mest känd som den starkast 
bidragande orsaken till livmoderhalscancer, är även en betydande riskfaktor för 
skivepitelcancer i svalget. HPV skulle också kunna vara en riskfaktor för skivepitelcancer i 
matstrupen, men tidigare studier visar tvetydiga resultat och förekomsten av HPV DNA i 
matstrupstumörer varierar mellan total avsaknad av viruset till närvaro i mer än 70%. 
Förklaringen till de varierande resultaten kan vara att förekomsten av HPV är olika hög i olika 
delar av världen, samt att man använt olika laboratorietekniker för att påvisa viruset. En annan 
möjlig förklaring är att förekomsten av viruset varierar med matstrupstumörens lokalisation. 
Eftersom man tidigare observerat ett samband mellan HPV och svalgcancer blev vår hypotes att 
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högt belägen skivepitelcancer i matstrupen är starkare förknippat med förekomst av HPV än 
tumörer belägna i den nedre delen.  
Arbete IV undersökte förekomsten av HPV DNA i förhållande till lokalisation av 
skivepitelcancer i matstrupen för nya fall i Stockholmsregionen mellan 1999 och 2006. 
Tumörens lokalisation fastställdes genom journalgranskning och HPV-förekomst detekterades 
med en PCR-metod. Resultaten visade att tumörerlokalisation inte är associerat med HPV.  
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